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ABSTRACT
CD98 is a glycoprotein with many important biological functions including amino acid
transportation, endocytosis regulation, and activation of the integrin β signal pathway. Studies have
shown the expression levels of CD98 are increased in the livers from fatty degeneration, although
the role of CD98 in non-alcoholic fatty liver disease (NAFLD) is not clear. The inflammatory
stress inside of the liver is considered one of the main driving forces for NAFLD development. It
has been well-studied that the inhibition of CD98 protects mice from colitis (inflammation). To
understand the role of CD98 in NAFLD, CD98 siRNA was loaded into the poly lactic acids (PLA)
nanoparticles (NPs) to directly inhibit the CD98 expression level in the liver of the high-fat diet
(HFD) mice. The decreased level of NAFLD-related markers and the improvements on the liver
tissue conditions were observed in the HFD mice with the treatment of CD98 siRNA-loaded NPs.
This study indicated that CD98 was important in the NAFLD progression, and downregulation of
CD98 can be an effective way for NAFLD treatment.
The mechanism of how plant-derived nanovesicles uptaken by cells remains unknown. In
this study, garlic-derived nanovesicles (GDVs) were isolated and digested with trypsin to remove
all surface proteins. Digested GDVs showed less uptake compared to undigested GDVs, confirming the surface proteins played an important role in endocytosis. On the cell side (Hep G2 cells,
HepG2), blocking CD98 receptors significantly reduced the uptake of GDVs. During the cellular
internalization of GDVs, microcopy concluded that some surface proteins of GDVs were co-localized with CD98. A total lysate of the GDVs surface showed a high presence of a mannosespecific binding protein: II Lectin. Blocking II Lectin on surface of GDVs using mannose highly
reduced the GDVs internalization which supports that direct interaction between II Lectin and
CD98 plays an important role in internalization. The GDVs also exhibited in vitro anti-

inflammatory effect by downregulating pro-inflammatory cytokines on HepG2 cells. This work
contributes to understanding a part of the GDVs internalization process and the cellular anti-inflammatory effects of garlic. Since CD98 expression level is increased in many diseases including
the NAFLD, the II Lectin-CD98 interaction can be utilized for the design of NPs for liver delivery.
In conclusion, this study indicates that CD98 can be used as the target for drug delivery,
and decrease the expression of CD98 can protect mice from high-fat-diet-induced liver damages.
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BACKGROUND

Plant-derived vesicles
In biology, the vesicle is a term that refers to the lipid-based structure which is generated
within both mammalian and plant cells. So far, the biogenesis of plant-derived vesicles is not
clear due to its complexity.[1] However, we can have an idea of the biogenesis and function of
plant vesicles throughout the examination of mammalian cell-derived vesicles. These vesicles
play a key role in cargoes (especially for proteins) storage and transportation. There are two major types of protein sorting mechanisms: Conventional Protein Secretion (CPS) and Unconventional Protein Secretion (UPS).[1, 2] The CPS requires signal peptide modification on the protein’s N-terminal site. The protein containing with signal peptide(s) can be transferred into the
Trans-Golgi Network (TGN) after synthesizing in the Endoplasmic Reticulum (ER), even with a
lack of the ER-Golgi Intermediate Compartment (ERGIC) in plants. The proteins are then packaged into vesicles and merged into membranes. However, CPS theory cannot explain the finding
of proteins without signal peptides or even non-protein materials (such as RNA) in apoplast
which is located outside of plant cell membranes.[2] These findings confirm the existence of
UPS, a signal peptide-independent mechanism, in the plant. In mammalian cells, UPS is also involved in the genesis of exosomes which are a type of extracellular vesicles.[3] These two types
of protein-sorting systems help in loading cargo from the cytosol into vesicles. Formation of vesicles are very complex which requires the recruitment of coat proteins (COPI, COPII, and clathrin), GTPases, and the ESCRT complex.[4, 5]
1.1.1

Edible plant-derived nanovesicles
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Edible plants in the diet help to reduce the risk of many kinds of diseases.[6] Recently, the
edible plant-derived nanovesicles (PDNs) provided a new angle to explain plant health benefits.[710] These vesicles contain DNA, RNA, proteins, polysaccharides, and lipids from their parent
cells.[7] The first PDNs-mediated interspecies communication was reported by Dr. Huang-Ge
Zhang’s group in 2013. They found that grape nanovesicles that were taken up by mouse intestinal
stem cells after gavage, which leads to upregulate the expression of Lgr5 and the potential mechanism was through the wnt/β-catenin signaling pathway.[11] Several nanovesicles obtained from
various edible plants were reported including carrot, lemon, broccoli, ginger, and so on. The nanovesicles derived from the varying edible plants were found to be associated with various biological effects such as anti-inflammation and anti-carcinogenic properties.[9, 12-14] PDNs have
shown an excellent ability to be internalized by mammalian cells both in vitro and in vivo. Moreover, edible PDNs have shown good biocompatibility to healthy tissues/cells. The biocompatible
advantage has been utilized for the encapsulatation of different drugs into PDNs, making them
become promising drug carriers. These studies suggest that plants can exert their biological functions on an animal by delivering the plant-derived active compounds, and can also be utilized as a
drug carrier. Recently, it has been further proved that the microRNA (miRNA) in ginger-derived
nanovesicles improves the mice gut health by influencing microbiota compositions.[15] They
showed the ginger-derived nanovesicles were taken into the Lactobacillaceae where serveral genes
expression in Lactobacillus rhamnosus are modulated by delivery of the ginger miRNA. For example, mdo-miR7267-3p, one of the ginger-derived miRNAs, could upregulate the indole-3-carboxaldehyde (I3A) expression, which can improve the function of the intestinal barrier by enhancing the expression of IL-22. This report also demonstrated the uptake mechanism of ginger
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nanovesicles by Lactobacillus rhamnosus via lipid fusion. However, it remains largely unknown
how PDNs are taken by mammalian cells.
1.1.2

Possible uptake mechanism for vesicles

Similar to the cell membrane structure, the vesicles are also in a lipid layer structure. This
property allows the vesicles to merge with the cell membrane simply by lipid fusion, which has
been proven using an abiotic system (e.g. liposomes).[16] Protein-free lipid bilayers can merge
spontaneously; however, the cell membrane is much more complex than the protein-free bilayers.
The extracellular space outside of cell membranes is enriched with the extracellular domains of
the transmembrane proteins, and most of the extracellular domains are glycosylated.[17] This
makes the cellular uptake of vesicles very complex.
Understanding the mechanisms of the mammalian cell-derived nanovesicles such as exosomes can elucidate potential internalization mechanisms for PDNs. The main uptake mechanisms
for mammalian exosomes include phagocytosis, clathrin-dependent, and clathrin-independent
pathways.[18-20] Phagocytosis is a special type of endocytosis that is majorly mediated by the
phagocytes. For most types of cells, the endocytosis of exosomes is usually dependent on the interaction between vesicle ligands and the cell receptors. For instance, Heparan Sulfate Proteoglycans (HSPG) on cell surfaces could be a possible receptor for exosome endocytosis. While it has
been reported that HSPG on the surface of exosomes is not involved in the internalization of exosomes.[20] Another study revealed that fibronectins on the surface of myeloma cell-derived exosomes have interactions with HSPG on target cells.[21] In addition, proteins on both the surface
of ovarian cancer cell-derived exosomes and ovarian cancer cells are important for uptake.[22]
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Liver
The liver is an important organ in vertebrate animals. The liver plays central roles in
many biological and physiological procedures including nutrients metabolism, energy storage,
processing the toxic compounds to less cytotoxic compounds, maintaining the balance of hormones, and breaking down the blood cells.[23-26] In addition to those important roles, the liver
also plays critical roles in other functions by coupling with other organs. For example, the liver is
involved in the digestion of lipid by secreting the bile which is an alkaline liquid mixture of cholesterol and bile acids. The bile will be temporally stored in the gallbladder, which is an organ
connected to the liver directly.[27] Since the liver is so important in maintaining life functions,
the loss of function in the liver will lead to serious health problems to the whole body or even
cause death.[28, 29]
Understanding the composition of liver cells is the prerequisite thing for understanding
liver diseases. The liver is made up by several kinds of cells including hepatocytes, liver sinusoid
endothelial cells (LESCs), Kupffer cells, and stellate cells. Among those cells, hepatocytes are
the major cell types in the liver which can take up to 60% of total cell number and 80% of the
weights. Hepatocytes play a critical role in maintaining the basic functions of liver, such as metabolism and filtration of poison metabolites, and innate immune regulation by secreting innate
immune proteins. An example of these innate immune proteins is the soluble CD14 protein
(sCD14) that is mainly secreted by the hepatocytes, and the function of this sCD14 on the lipopolysaccharides (LPS) signaling pathway has been shown in a concentration-dependent manner.[30] Liver sinusoidal endothelial cells (LSECs) form the sinusoid, which is the thinnest blood
vessel in the liver.[31] The sinusoid separates the contents (for example, Kupffer cells and blood
cells) inside the capillaries and the cells (including hepatocytes and stellate cells) outside. These
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unique properties make the LSECs important in maintaining immune homeostasis, providing nutrients, and recycling waste. Kupffer cells are a special type of macrophages that are located inside the liver sinusoid.[32-35] Kupffer cells can cause either liver damage or repair the liver
damages depending on the immune environment as well as the ongoing metabolism. This is because the Kupffer cells have at least two types of phenotypes, the proinflammatory M1 phenotype, and the several different M2 phenotypes. The M2-type Kupffer cells can inhibit the inflammation and enhance the wound healing, however, more studies are required before promoting
Kupffer cells with a specific M2 conversion for certain liver damages.[34] The hepatic stellate
cells (HSCs) are distributed within the spaces between LESCs and the hepatocytes.[36] HSCs are
important cells for secreting collagen and excessive collagen will lead to liver fibrosis.[37] The
HSCs contain up to 80% of the total vitamin A inside the human body and are usually called vitamin A-storing cells. Vitamin A (majorly retinoid) levels inside the HSCs are highly associated
with liver fibrosis. The lower the retinoid in HSCs, the easier it to induce liver fibrosis in the
rats.[38] As mentioned before, the HSCs barely interact with the Kupffer cells directly as they
are separated by the LESCs. However, the HSCs interact with Kupffer cells during liver inflammation. It is important to know that all the cells in the liver are not isolated, in fact, they work
with each other tightly. For example, one important function of LESCs is to recruit lymphocytes
which are required by the Kupffer cells, hepatocytes, and stellate cells. The Kupffer cells initiate
the signaling to simulate the expression of adhesion protein on LESCs by the release of the proinflammatory signals. Once the lymphocytes bind to the sinuous in a selectin-independent manner, the hepatocytes form the firm adhesion between LESCs and lymphocytes by releasing paracrine factors. The transmigration of lymphocytes then activates the HSCs through the release of
chemotactic factors.[31]
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1.2.1

Common liver diseases

Table 1.1 summarizes some common factors which lead to liver damages. Many issues
including viral infections, immune system dysfunction, and even hazards in our diets can damage
the liver directly or indirectly. [39-47] The common viruses that lead to liver damage include
hepatitis A virus, hepatitis B virus, and hepatitis C virus. Treatments for those virus infections
are varied. For hepatitis A infection, there is no recommended medication since this infection can
be cured naturally. For hepatitis B or hepatitis C virus-infected patients, antiviral medication is
required to reduce liver damages.[46] No drug can cure the hepatitis B virus infections; however,
Hepatitis B virus infection can be effectively prevented by the vaccine.[48] Unlike hepatitis B,
no vaccines are available for hepatitis C. However, the hepatitis C virus infection can be cured
by the treatment with the proper medications. Contaminated food is a risk for induction of liver
damages, too. The aflatoxin is an example of such a toxin. There are four types of aflatoxins, i.e.,
aflatoxin B1, B2, G1, and G2, which are majorly produced by Aspergillus flavus and Aspergillus
parasiticus (Figure 1.1 A). Among those, the aflatoxin B1 (AFB1) has shown the strongest hepatotoxicity. In the liver, AFB1 will be converted into the intermediate called AFB1-exo-8,9 epoxide (AFBO, Figure 1.1 E), which will insert into the gene, leading to the mutation of the tumor
suppression gene (p53), and eventually lead to liver cancer. These aflatoxin-producing fungi exist everywhere, and they could contaminate crops, peanuts, as well as other nuts during the harvest or storage procedures. In addition, aflatoxin can also be found in milk, meat, and eggs due to
feeding animals with contaminated food.[39] According to the United States Food and Drug Administration (FDA), aflatoxins contamination in food cannot be eliminated and this contamination threats about 4.5 billion population worldwide.
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Figure 1.1: Structure of four types of aflatoxin and its metabolite AFBO.
(A) Alfatoxin B1, (B) Alfatoxin G1, (C) Alfatoxin B2, (D) Alfatoxin G2, (E) AFBO
Table 1.1 Summary of common liver diseases and the corresponding therapeutics.

Disease Names

Mainstream Therapeutics

Estimated Affected Population

References

8
Hepatitis A

No specific medication needs and will

1.4 million per

[40]

year

cure after several weeks
or months
Hepatitis B

Antiviral medicines, such as entecavir,

About 257 mil-

[41]

lion infections.

tenofovir, lamivudine,
adefovir, and telbivudine
can be used to protect the
liver damages. The vaccine is usefully in prevention of hepatitis B.
Hepatitis C

Antiviral medi-

130-170 million.

[46]

No published

[42]

cines such as the sofosbuvir (sovaldi), simeprevir (olysio), daclatasvir (daklinza) and so on.
Alcohol abuse

Stop drinking alcohol and could take

data showed the exact

some vitamins. Liver

number of populations

transplant is an available

being affected. However,

option if the liver dam-

the amount of alcohol

ages are serious.

bigger than 14 g of

9
alcohol (a 12 oz can of
beer) is considered as the
misuse of alcohol.
NAFLD

No drug availa-

882 million.

[49]

ble.
Autoimmune hepatitis

The drugs such as pred-

1-2 per 100,000 popula-

nisone are used to sup-

tion per year.

[47]

press the immune system.
Bile Duct Cancer

Surgery to remove the

It is not a common can-

cancer.

cer; the incidences are

[45]

varied in different areas.
The highest incidence is
in South Korea (3 per
100,000) while the lowest incidence is in UK
(0.66 per 100,000)
Unclean food such as aflatoxin B1 contaminated
peanuts

No therapeutic available.

4.5 billion people is affected.

[39]
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1.2.2

Fatty liver diseases

Among the possible liver damages, the most common liver disease right now in the U.S.
is non-alcohol fatty liver disease (NAFLD).[49] Unlike healthy liver contains a very limited
amount of fats. Fatty liver diseases (FLDs) are a condition which excessive amounts of fat is
found in the liver. Typical FLDs are usually referred to as a liver that contains more than 5-10%
(total liver weights) of fat.[50] The FLDs can be divided into two categories based on the consumption of alcohol: the alcohol-induced fatty liver disease (ALD) and NAFLD, which the latter
refers to fatty liver diseases that are alcohol-independent.[51] FLDs encompass a broad spectrum
of liver diseases including steatosis, steatohepatitis, cirrhosis, and liver cancer.[52] The longterm over-dose consumption of alcohol accumulates the damages on the liver is still the major
contributor to the pathogenesis of ALD.
NAFLD is a disease with a similar hepatic histologic pattern to that of alcohol-induced fatty
liver disease, while the patients only intake a little amount of alcohol or even never consume the
alcohol before. NAFLD is usually characterized into two subtypes: 1) non-alcoholic fatty liver
(NAFL) which only shows excessive lipid accumulation, and 2) the more serious nonalcoholic
steatohepatitis (NASH) which is the inflammatory condition indicated by lobular inflammation.[53] NAFLD is now the most common liver disease which affects about 25% of the general
population in the world.[43] The prevalence of NAFLD in the United States has increased, which
is expected to affect more than 100 million people by 2030.[54] Without proper treatments,
NAFLD can develop into NASH and further develop into more life-threatening diseases such as
liver fibrosis, cirrhosis, and even liver cancer. The pathogenesis of NAFLD is not fully understood
which causes difficulties in drug development.[54] To date, no drug is approved by the FDA for
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the treatment of NAFLD. The current first-line therapeutic strategy for NAFLD is aimed to reduce
the patients’ body weights via changing the lifestyle, i.e., a healthy diet and moderate exercise.
Recently, a “multi-hit” theory was proposed for the pathogenesis of NAFLD. According
to this theory, pathogenesis results from the combination of factors including oxidative stress, lipid
metabolism, immune response, dietary, gut bacteria-derived LPS, and so on.[54-56] Among those
factors, oxidative stress is considered as the major factor which promotes the disease from NAFL
to NASH. Thus, the antioxidants can be used as candidates for NAFLD therapy. In a clinical trial,
vitamin E (800 IU/day) shows significant improvement in NASH when compared to the placebo
(ClinicalTrials.gov number, NCT00063622.).[57]
Different types of liver cells are involved in the NAFLD development. In NAFLD, the
hallmark is the extra accumulation of fats in the hepatocytes.[58] And this abnormal fatty acid
accumulation can cause lipotoxicity to the hepatocytes by increasing the reactive species of oxygen (ROS) level.[56] In fact, ROS production is important in the NAFLD progression. In a clinical study, the ROS levels in the liver of obese volunteers (including the obesity without NAFL,
obesity with NAFL, and obesity with NASH.) groups are found to be higher than that of the
health volunteers’ livers. In addition, only the ROS level in obesity with NASH is significantly
higher than the level in the health group. A further study indicated the hepatic gene damages
were only found in obesity with NASH.[59] The stresses on hepatocytes might lead to the release
of cytokines such as the Monocyte chemoattractant protein-1 (MCP-1/CCL2), interleukin-6 (IL6), IL-18, CD36, and tumor necrosis factor alpha (TNF-α). The upregulation of CCL2, which is
observed in both ALD and NAFLD patients, promotes the macrophages recruitment in the liver
and contributes to liver damage, inflammation, and steatosis.[30] Hepatic macrophages in liver
sinusoids and the Kupffer cells play key roles in the development of NAFLD. According to the
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“multi-hits” theory, the Kupffer cells can mainly mediate the inflammatory response (second
hit). Recently studies support that the different subtypes of Kupffer cells played different roles in
the immune response.[35] The M1 Kupffer cells play a role in the pro-inflammation effects in
the NAFLD, while the M2 (M2a, M2b, and M2c) subtype exhibit a protective effect on the liver.
As reported, the M1/M2 cell ratios are elevated in both NAFLD and ALD. The M2 Kupffer cells
could decrease the M1 Kupffer cell-induced inflammation in the liver by causing the apoptosis of
M1 Kupffer cells via secretion of IL-10.[60] The HSCs activation is the predominant cause for
the development of liver fibrosis. Alpha smooth muscle actin (α-SMA) is used as a marker for
activation of HSCs and the activated HSCs secrete collagen I. The morphology of HSCs in normal conditions is a star-like shape and the activated HSCs are in myofibroblast shape.[61] The
molecular mechanism under the activation is complex which involves many proteins i.e., peroxisome proliferator-activated receptor gamma (PPARγ), Transforming growth factor-β1 (TGF-β1),
LIM homeobox protein (Lhx2), platelet-derived growth factor (PDGF)-receptor, and so on.[62,
63] Current studies support that TGF- β1 plays a central role in enhancing the expression of αSMA. The ligand of PPARγ showed potential for reducing the expression in TGF- β1-induced αSMA and collagen expression.[62] In summary, the development of NAFLD is the result of the
combination of many factors including the multi-stresses caused liver damages, hepatic macrophages activation, and the HSCs response (activation and collagen release). Those factors together promote the liver damages into NAFL to NASH, liver fibrosis, and even the liver cancer.
This fact also implies that the ideal drug for NAFLD treatment should be able to modulate several signaling pathways and affect the different liver cells at the same time.
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Lectin
Lectin, a set of proteins which bind to the specific carbohydrates, is produced by the animal, plant, fungi, and bacteria.[64-67] The interaction between lectins and carbohydrates is mediated by the carbohydrate recognition domain (CRD).[67, 68] Thus, the lectins are considered
as the “antibody” for carbohydrates. Due to this unique recognition between lectin and carbohydrates, the lectins have been developed into important analytical techniques for carbohydrates
research including the lectin array assay and the lectin affinity chromatography (LAC).[69, 70]
For example, plant-derived lectins can be used as biochemical reagents to differentiate between
different blood types in the ABO blood system; this is based on the lectin’s abilities to differentiate the differences in terminal carbohydrate patterns on erythrocytes surface.[71] Carbohydrates
are involved in many biological processes including nutrient, protein post-transcription modifications, and species recognition.[72] And the carbohydrates are found in the animal, plant, bacteria,
and even virus.[72-75] Thus, it is not surprising that many interspecies recognitions are mediated
by the lectin-carbohydrate interaction.[66, 67, 76] In addition, the functions of lectins are highly
varied and dependent on the role of the carbohydrates and the glycoproteins. Glycosylation, an
important method for proteins post-transcription modification, will affect the biological functions
of proteins. The normal cells usually have different glycan modifications when compared to the
cancer cells and the drug-resistant cancer cells.[70, 77] The lectin-carbohydrate recognitions also
form the basis for innate immune response.[78] In summary, the biological function of lectin is
varied and dependent on the functions of glycoproteins or carbohydrates.
1.3.1

Lectins derived from animals and plants

The lectin classification is complex since the criteria for the classification are various.
The animal lectins are generally divided into two classes, the intercellular lectins, and
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extracellular lectins which include the transmembrane lectins. Generally, in mammalian cells,
intercellular lectins are involved in the regulation of inflammation and apoptosis, while extracellular lectins are considered to play the important role in signaling transduction.[79] Interestingly,
the galectin-3, a beta-galactoside binding lectin, is found in both intercellular and extracellular
space.[80] The intercellular galectin-3 inhibits cell apoptosis, while the extracellular galectin-3
serves as the ligand in activation of the surface glycoproteins including glycoprotein CD98, galectin-3 binding protein (G3BP), and so on.[79, 81-86] The asialoglycoprotein receptor is the
transmembrane lectin on the surface of hepatocytes which shows a strong affinity to galactose.
The function of the asialoglycoprotein receptor is to bind the proteins with galactose modification in the terminal.[87] This asialoglycoprotein receptor is reported to be mainly present on the
surface of hepatocytes. Thus, this receptor is considered an important target in liver disease treatments.[88]
Plant lectins can be classified based on their subcellular location, binding substrates,
structure similarity in CRDs, or their endogenous role.[89, 90] Based on the endogenous role, the
plant lectins can be divided into three lectin families: 1) jacalin-related lectins family, 2) Cucurbitaceae phloem lectin family, 3) monocot mannose-binding lectin family.[90] Garlic is a monocotyledon and several different mannose-binding lectins have been identified from garlic including Allium sativum agglutinin (ASA) I (ASA I), ASA II, and ASA III. ASA II is a dimer formed
by two II lectins. As shown in Figure 1.2, the garlic-derived lectin, II Lectin, is a protein with ten
β-sheets that form the β-prism II fold pattern.[91] Three typical mannose-binding motifs
(QXDXNXVXY) were found in the amino acid sequence.[92] Plants contain a large number of
lectins which are considered as the plant strategies against bacteria, fungi, pests, and viruses.[93]
For example, one group has designed pest-resistant transgenic rice by the incorporation of garlic
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leaf lectin.[94] In addition to the lectin's role in interspecies communication, plant lectins are
very important in glycan analysis. Most of the lectins used in the lectin array are derived from
plants.[95]

Figure 1.2: The amino sequence and structure of II Lectin.
(A) The sequence of II lectin. The motif of the mannose-binding site is in bold and underline.[91] (B) The structure of II Lectin. The β-sheets are shown in purple. The structure is
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obtained from the protein data bank (PDB) with the PDB code 1BWU (chain D). The structure
of 1BWU (chain D) is visualized by using Chimera.[96]
1.3.2

Lectins in disease treatment

Both plant and animal lectins show their potentials in treating diseases.[97] Lectins are
mainly used in disease treatments in two distinct ways. The first strategy is to exert the lectin
functions straightly. To date, accumulated studies have explored the potential treatments by using lectins in different diseases, including cancer, lung fibrosis, HIV infections, etc.[98-100] The
other strategy is to take advantage of the strong affinity between carbohydrates and lectins to
achieve drug targeting delivery. Nanoparticles (NPs) decorated with lectins or carbohydrates on
the surface have shown enhanced delivery efficiency.[87, 97, 101] Significantly different carbohydrate profiles between the cancer cells and normal cells have been found.[102, 103] Screening
the lectins which recognize the disease's unique carbohydrate patterns will contribute to developing the disease-targeted therapy in the future.
CD98
CD98 is a heterodimeric protein which is made by a heavy chain and a light chain (Figure
1.3).[104] The CD98 heavy chain (CD98hc) is encoded by the human SLC3A2 gene. The light
chain of CD98 (CD98lc) can be any of the following proteins: large amino acid transporter 1
(LAT1), large amino acid transporter 2 (LAT2), and glutamate transporter called system
xc−.[105-107] The CD98hc and CD98lc are spatially close to each other and form the CD98 via
ligation of a disulfate bond.[107-109] The CD98hc is required for the CD98lc to work functionally and in turn, the presence of CD98lc can protect CD98hc from degradation.[110] One fact is
that CD98 is existed in all the actively proliferation cells.[111, 112] This indicates the important
role of CD98 in maintaining cell proliferation and activation. Moreover, CD98 is involved in the
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control of cellular internalization, nutrients intake, immune activation, and inflammation promotion.[81, 107, 113-118] CD98 is highly expressed in many diseases and multi-roles of CD98
make it a potential target for the development of therapeutics.

Figure 1.3: The structure of the CD98 (CD98hc and LAT1) complex.
The CD98hc is labeled in yellow and the LAT1 is labeled in cyan. The structure is obtained from
the protein data bank (PDB) with the PDB code 6IRT. The structure of CD98 is visualized by using Chimera.[96]

18
1.4.1

CD98 heavy chain

The CD98hc is a single-pass transmembrane protein, and the sequence of CD98hc can be
divided into four sections, i.e., the extracellular domain (ED), transmembrane domain (TM1’),
juxtamembrane domain, and the cytoplasmic domain (N-terminal).[110, 119, 120] All four domains play important roles in CD98hc mediated biological functions. The ED of CD98hc is
made of eight repeats (domain A) and eight β-streets (domain C).[110, 119] As reported, the ED
of CD98 is important in maintaining the cellular adhesion of cells. The TM1’ of CD98hc is the
place for the binding of LAT1, and the TM1’ is the most important section in interacting with the
integrin β signal pathway. This integrin interaction was studied using the chimeric protein
(C98T69E98, which has the ED and cytoplastic domain from CD98, and TM from CD69 protein) that has replaced the CD98 TM1’ with a CD69 TM domain resulting in the disruption of the
interaction with integrin β1. While the chimeric protein (C69T98E69, which has the ED and cytoplastic domain from CD69, and TM from CD98) shows the interaction with integrin β1. This
fact indicated the TM of CD98 plays the center role in activating the integrin signal pathway.
The sequence between the cytoplastic domain and TM is called the juxtransmembrane section.
The juxtransmembrane and TM of CD98 are highly conserved, which suggested that they might
play a key role in some unique cellular functions. The cytoplastic domain and juxtransmembrane
sections show inhibition effects in the CD98hc-activated the integrin β signaling pathway.[113,
120]
The sequence of CD98 protein (human) is shown in Figure 1.4. The molar mass calculated from this CD98hc sequence is around 67 kDa. However, in most situations, the molar mass
of CD98hc is about 85 kDa.[81] The difference in the mass is caused by the fact that CD98 is a
protein with heavy glycosylation in the CD98hc.[81] Many sites in CD98hc are predicted as
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potential sites for glycosylation. Recently, cryogenic electron microscopy (cryo-EM) has become
a powerful tool in interpreting the structure of the protein, especially for the transmembrane proteins.[121] A study regarding illustration of CD98 (CD98hc-LAT1 complex) structure using
cryo-EM confirmed that there are four new N-glycans modification sites on the ED of
CD98hc.[119] Even though the CD98 used in this study was produced the HEK293 cells without
the key enzyme to complete full glycosylation, heavy mannose modification on CD98hc was
found in the N-glycans modifications on ED of CD98hc. The CD98hc ED mannose modifications are not likely to be necessary for the CD98 complex formation, however, the extracellular
sugar antenna could act as potential binding sites for lectin-CD98 interaction.[81] The cryo-EM
indicated that the TM1’ forms a helix to helix interaction with the TM4 in the LAT1 and the Nterminal TM1’ of CD98hc is closely interacting with the system xc−.[109, 119]

Figure 1.4: The amino acid sequence of full-length CD98.
The CD98hc protein can be divided into four sections by its location to the cell membrane. The
four sections from extracellular to the cytosol are the extracellular domain (215-630), transmembrane domain (185-205), juxtransmembrane (161-184), and the cytosol domain (1-160). The sequence of CD98 is reported in the literature.[119]
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1.4.2

CD98 light chain

To date, three complete CD98 heterodimeric structures have been characterized using the
cryo-EM.[109, 119, 122] Those three light chains (LAT1, LAT2, and system xc−) are all bound
to the CD98hc TM1’ via the disulfate bridges, and all three light chains are identified as amino
acid transporters. LAT1 and LAT2 are the larger amino acid transporters which are functionalized to transfer large neutral amino acid (L-leucine and L-tyrosine) in a Na+-independent way.
LAT1 affinities to large neutral amino acids are much higher than that of LAT2, while the LAT2
show a more broad ability in transporting the small amino acids such as alanine. Recently cryoEM studies of CD98hc-LAT1 and the CD98hc-LAT2 contribute to the understanding of this difference in amino acid transport efficiency. The pocket, the substrate-binding site, is slightly different in the LAT1 and LAT2. The amino acids in the LAT2 pocket (Thr86, Tyr396, Tyr399, and
Tyr430) are slightly larger than the amino acids in the LAT1 pocket (Ser96, Trp405, Val408, and
Phe439). The large amino acids inside the pocket of LAT2 might contribute to the recognition of
the small amino acids.[122] The system xc− is the amino acid transporter that can take the exocellular L-cystine into cells and export the intercellular L-glutamate out of the cells.[123] The system xc− is very important due to the cystine which is the key material for the production glutathione (GSH) that plays important roles in protecting cells from ROS.[124] As we know, the ROS
level inside the cancer cells is usually higher than that in the normal cells because of the higher
activities. System xc− is overexpressed in the tumor cells and contributes to maintaining intercellular redox status.[125] Thus, the inhibition of system xc− enhanced the cancer cell cisplatin-induced cytotoxicity synergistically.[126] Targeting the of system xc− can affect the nutrients and
oxidative stress at the same time. Since all the three different CD98lcs are bound to the TM1’ of
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CD98hc to form the CD98, CD98 protein can be a very important target for modulation of redox
status, nutrients, and other signaling pathways.
1.4.3

The role of CD98 in disease

CD98 biological functions are mainly related to fundamental functions of the CD98hc
and CD98lc, which involves the nutrients intake, redox enhancement, and integrin signaling
pathway modulation. Thus, it is no wonder that CD98 is upregulated in cancers and inflammatory diseases (colitis and NAFLD).[127-129] The upregulation of CD98 in cancer and inflammatory diseases promotes cell survivability against the harsh cell stresses. The role of CD98 in cancers includes the drug resistance to chemotherapeutic and the resistance to radio-chemotherapy.[14] In addition, the upregulation of CD98 may lead to poor prognostic outcomes.[130]
CD98 inhibition increased the chemosensitivity in cancer cells when utilized in the design of the
co-delivery nano-formulations to synergistically enhance chemotherapy.[131] Another CD98based anticancer therapy is using an anti-CD98 antibody, IGN523. The in vivo study showed that
the IGN523 decreased the amino acid uptake and increased the antibody-dependent cellular cytotoxicity.[118] CD98 is overexpressed in the colitis and governs the intestinal homeostasis via interacting integrin β1 proteins, leading to the activation of focal adhesion kinase (FAK).[128]
Thus, decrease the expression of CD98 will be an effective way for attenuation of colitis.[132]
1.4.4

The role of CD98 in internalization regulation

CD98 trafficking is dependent on the clathrin-independent endocytosis (CIE) pathway,
the recycled CD98 can be incorporated back into the membranes under the control of a small
GTPase, Arf6.[113, 133] Thus, the CD98 dependent internalization requires the consumption of
energy (GTP, Guanosine-5'-triphosphate). In normal tissue, the expression level of CD98 is relatively low, however, CD98 is usually overexpressed in cancer or inflammatory tissues (i.e., IBD
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and colitis).[117, 128] In our recent study, CD98 has been found as a potential inducer for nonalcohol fatty liver disease (NAFLD).[129] NAFLD is a condition in which fat accumulation inside of the liver cells affects patients with little or no alcohol consumption. Our group also found
that CD98 expression level is even higher in the hepatocellular carcinoma (HCC) patients’ livers.[129] The differential expressions of CD98 between normal conditions and disease conditions make CD98 an ideal target for drug delivery and therapy. This idea has been verified by
different research groups via targeting either CD98hc or CD98lc (LAT1). It was reported by Dr.
Merlin’s group that NPs modified with the CD98hc antibody Fab’ sections on their surfaces were
preferably taken into the colon tissues of the DSS-treated mice group.[115] Since the major role
of LAT1 is transporting the neutral amino acid (such as glutamate) into the cells, glutamate has
been added onto the surface of PLGA NPs to enhance the targeting ability to the tumor.[106]
Taken together, glycoprotein CD98 can be a promising receptor for the internalization of NPs.
Nanoparticles for NAFLD treatments
Nanoparticles (NPs) refer to small particles which have a size up to 500 nm in diameter.
The application of NPs is varied from therapy, biosensor, image contrast reagent, and diagnosis.[134-144] In this study, the NPs we discussed are referring the NPs used for drug delivery.
The NPs for drug delivery usually consist of three elements including the matrix (NPs forming
materials), cargoes (drugs or therapeutic molecules), and the surface ligands.[145, 146] The NPs
can be made from many types of material, including metal, polymer, lipid, and silica.[145-149]
Various drugs such as hydrophilic drugs, hydrophobic drugs, and large molecules (protein,
mRNA) can be loaded into the NPs alone or in a combination way.[132, 150] In general, the advantages of drug delivery using NPs are drug protection, targeted delivery, and controlled release.[132, 151] As we discussed in the liver introduction section, one of the liver’s functions is
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to filtration of the toxic compounds (including drug molecules). Thus, most of the drugs will accumulate in the liver naturally and this property of the liver makes the drug delivery to other organs (except the liver) difficult. However, the study regarding the formulation of NPs in drug delivery to the liver using NPs is still necessary.[152] As mentioned before, the liver is made of
different types of cells including the hepatocytes, HSCs, LESCs, and Kupffer cells. Different
cells are playing different roles in the NAFLD. Thus, achieving the cellular targeted drug delivery to the liver will contribute to the therapeutic effects by increasing the drug concentration in
desired cell types and reducing the side effects on other cells.
In general, the NPs internalization by cells is determined by many factors such as the
size, shape, zeta potential, and surface modification (ligands).[153] Different cells have different
preferences in the uptake of NPs. The NPs with a larger size (400-500 nm in diameter) will be
eliminated by the Kupffer cells and the small size will reduce the macrophage depletion.[154]
Interestingly, Kupffer cells prefer to uptake NPs with positive charges. However, negatively
charged surfaces on NPs might interact with the protein in blood to form the protein corona,
leading to macrophage clearance.[152] The Kupffer cells make up to 80% of the total macrophages in the whole body, thus, the Kupffer cells clearance of NPs should be taken into consideration if the NPs are designed to target other cells in the liver (exclude the Kupffer cells). One
possible way to avoid the macrophages phagocytosis is to coat the NPs’ surface with a poly (ethylene glycol) (PEG) layer.[155-157] These neutral hydroxy groups reduce the macrophages uptake in vivo by reducing the NPs interaction with the NPs. In addition to the Kupffer cells, another major barrier for NPs to be delivered to the hepatocytes is the sinusoid (LESCs). The sinusoid fenestrations (i.e., openings) size is about 100 to 150 nm in diameter.[158] In other word,
NPs with a size smaller than 150 nm are capable of passing this physical barrier. In addition to
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the size, the ligands on the surface of NPs could help to achieve the maximized hepatocyte delivery. For example, the asialoglycoprotein receptor (ASGPR) is a c-type lectin that is expressed on
the surface of hepatocytes. This surface lectin (ASGPR) showed a strong binding affinity to the
galactose and can capture the proteins with the galactose in the terminal. Thus, the galactose is
chosen to modify the surface of NPs to enhance the hepatocytes targeting ability.[139] Other
hepatocytes targeting ligands are summarized in the Table 1.2.
Table 1.2: Summary ligands and the receptors for hepatocytes targeted delivery

Ligands

Receptors

Reference

Galactose

Asialoglycoprotein receptors

[139, 140, 146, 159]

N-acetylgalactosamine

Asialoglycoprotein receptors

[137, 160]

Lactobionic acid

Asialoglycoprotein receptors

[148, 161, 162]

Pullulan

Asialoglycoprotein receptors

[163, 164]

Hyaluronic acid

CD44

[49, 138, 165]

Countless studies have been done to explore the NAFLD treatments using nanoparticlebased drugs. Those NPs can be both synthesized NPs or natural existing NPs which are referring
to mammalian cells-derived exosomes and plant-derived nanovesicles.[166-169] The NPs for
NAFLD treatment were summarized and categorized by the NPs materials.
1.5.1

The polymeric NPs for NAFLD treatment

The most famous polymers in drug delivery are the ploy (lactic acid) (PLA) and the poly
(lactic-co-glycolic acid) (PLGA) (Figure 1.5). PLA and PLGA are both approved by the FDA for
drug delivery and showing high biocompatibility and biodegradation.[170] Since CD98 plays an
important role in the NAFLD progression, our group has designed a formulation of NPs
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consisting of PLA to deliver CD98 siRNA to silence the CD98 in vivo. The average size of the
NPs was about 270 nm and the zeta potential was slightly negative. The surface of the NPs was
covered by the polyvinyl alcohol (PVA) to reduce the interaction with the macrophages in vivo.
In the in vivo distribution assay, we found about NPs were accumulated in the 18% of hepatocytes of the high-fat diet (HFD) group and about NPs were accumulated in the 5% of macrophage-like cells in HFD mice group. This indicated the formulation we used can effectively deliver the drug into hepatocytes and avoid the macrophage depletions to some extent. This formulation decreased lipid accumulation in HFD mice and reduced the expression of pro-inflammation cytokine.[171] Along with the PLA and PLGA, many polymers are under evaluation. Wendi
Teng et al. reported a formulation to deliver resveratrol to the liver for NAFLD treatment. They
synthesized the NPs using a partially oxidized starch (30% oxidized) and enable the hepatocytes
targeting ability by adding the galactose (gal) to the surface of NPs. They used the live image
system to show the drug accumulation in vivo and found the gal-modified NPs accumulated more
in the liver than that in free dye and non-targeted NPs treated groups.[172]
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Figure 1.5: Structure of PLGA, PLA, and their breakdown products.
(A) Structure of PLGA and its breakdown products lactic acid and glycolic acid. (B) Structure of
PLA and its breakdown products lactic acid. Both lactic acid and glycolic acid are existed in
cells and can be metabolized.

1.5.2

The lipid-based NPs for NAFLD treatment

Muralidhara RaoMaradana et al. reported a liposome formulation in delivering curcumin.
Their strategy was based on delivering the anti-inflammation compound (curcumin) into the dendritic cell (DCs) in the liver, leading to the inhibition of the inflammation environment and
switch of the cell phenotypes. The liposomes were made by using the egg phosphatidylcholine
(EPC) and cholesterol in the mass ratio of 7 to 3. The size of this liposome was about 120 nm,
however, the macrophages targeting ability might be caused by the lack of PEG-coated on the
surface. [173] Xiaona Liu et al. reported a liposomal formulation in NAFLD treatment by inhibiting fatty accumulation.[174] This liposome was made by L-α-phosphatidylcholine and cholesterol in the mass ratio of 20 to 1, and the average size of this liposome was about 70 nm. This
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liposome showed strong accumulation in the liver in vivo and can retain in the liver up to 24 h
after administration. And the delivery of liposomal deoxyschizandrin to adipocytes reduced the
lipid droplet accumulations.
1.5.3

Inorganic NPs for NAFLD treatment

Unlike lipid-based or polymeric NPs mentioned which require the drug cargoes for treating NAFLD. The inorganic NPs have shown potential for NAFLD treatment due to their low cytotoxicity and unique physical properties. For example, the cerium dioxide (CeO2) NPs (CNPs)
exhibited strong anti-inflammatory effects based on the following reasons: 1) the small size of
NPs caused a large ratio between surface area and volume, 2) the ability to switch the Ce3+ and
Ce4+ on the surface of CNPs.[175] The biodistribution of CNPs is dependent on the administration routes. For intravenous administration, most of the CNPs are accumulated in the spleen followed closely by the liver. CNPs were also found in the lungs and the kidneys after the i.v. injection. The CNPs can stay inside the liver for up to a month, this enables the CNPs to exert the
long-term anti-inflammation effects in vivo.[176] Silvia Carvajal et al. synthesized CNPs with
the size of 4 nm, and they found those CNPs could decrease the lipid droplets, cholesterol, and
cytokines accumulation in the liver after i.v. injection in the methionine and choline deficient
diet (MCDD)-induced rats.[177]

28
2

CD98 SIRNA-LOADED NANOPARTICLES DECREASE HEPATIC STEATOSIS IN
MICE
Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common liver disease (with a prevalence

of about 25%) in the world. Unfortunately, no drug is available for NAFLD treatment. The hallmark of NAFLD is the accumulation of excessive fat in the hepatocytes which are not the cells
supposed to functionalize for large amount of fat storages. The NAFLD can be divided into two
stages, the stage without inflammation is called NAFL and the stage with inflammation is called
NASH. NASH can develop into more lethal diseases including fibrosis, cirrhosis, and liver cancer. Although the pathogenesis of NAFLD is not that clear, many different signaling pathways as
well as different types of cells inside the body are related to the development of NAFLD. It has
been shown that chronic liver inflammation can be the main driving force for this disease development.[178]
Currently, some therapeutic methods for NAFLD are under clinical evaluation. The exciting therapeutic effects of obeticholic acids (OCA) in the clinical trials are the best example to
support the idea that NAFLD treatment may require a modulation of many signaling pathways at
the same time. OCA, 6α-ethyl-3α,7α-dihydroxy-5-cholan-24-oic acid, is an agonist of the farnesoid-X-receptor (FXR) which has involved in many important biological processes including
lipid metabolism, suppresses inflammation, and immune modulation in the NAFLD.[179-181]
However, the serious side effects of the OCA might impair its therapeutic effects in
NAFLD.[180] It is urgent to explore the new therapeutics for NAFLD treatment.
CD98 is a transmembrane glycoprotein which is existed in almost all types of cells, this
fact implies the importance of CD98 in maintaining cell functions. Indeed, CD98 has shown
broad functions in biology including the nutrients transportation, lipid metabolism,

29
inflammatory, innate immunity, and adaptive immunity.[104, 123, 132, 182, 183] Thus, it is rational to expect that many different signaling pathways in different cells can be modulated by
targeting CD98. Moreover, CD98 is highly expressed in the disease condition and CD98 has
shown the potential to be a target for disease treatment. For example, the signaling pathway in
maintaining the acute myelogenous leukemia (AML) microenvironment is disturbed by CD98
antibodies.[184] Another CD98-targeting therapeutic approach is using the CD98 siRNA to silence the CD98 protein expression. This method requires the siRNA can be delivered into the cytosols of targeted cells. However, it is difficult for a bare siRNA to pass the membrane due to the
negative charges, and the bare siRNAs might be degraded rapidly before they arrive at the lesions.
It has been proven that NPs can be an efficient platform for siRNA delivery with serval
advantages: 1) nucleic acid protection, 2) targeted delivery, 3) controlled release. To date, siRNA
has been loaded into many types of NPs including liposomes, polymeric NPs, and so on. Deliver
CD98 siRNA to the lesions using NPs has been proven to be an effective way in the treatment of
inflammation in the gastrointestinal systems including colitis and the inflammatory bowel disease (IBD).[114, 132] As demonstrated in the literature, the administration of CD98 siRNA NPs
will lead to the small accumulation of NPs in unwanted tissues, and no damages were found in
the major organs (heart, liver, lung, spleen, and kidney) by the H&E staining and the blood cells.
These indicated that no serious side effects for the unwanted delivery of CD98 siRNA.[131]
The goal of this study is to verify the CD98 potential in NAFLD treatment. In this study,
the CD98 siRNA loaded PLA NPs was fabricated using a double emulsion method. The size of
NPs was examined by the dynamic light scattering method (DLS), scanning electron microscope
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(SEM), and atomic force microscopy (AFM). The high-fat diet included NAFLD mice were used
to evaluate the therapeutic effects of NPs.

Methods and materials
2.2.1

Materials

Machines:
The instruments used in this study included the Leo 1450VP scanning electron microscope
(New York, NY), SPA 400 AFM (Seiko Instruments Inc., Japan), 90 Plus/BI-MAS sizer
(Brookhaven Instruments Corporation, Holtsville, NY), ZetaPlus (Brookhaven Instruments Corporation, Holtsville, NY), Synergy H1 plate reader (BioTek, Winooski, USA), and Digital Sonifier
450 (Branson, Danbury, CT).
Reagents:
CD98 siRNAs (sc-35033 and sc-35034) were purchased from Santa Cruz. For the antibody, NF-κβ (sc-372) and CD98 (sc-9160) were purchased from Santa Cruz. CD11b (M1/70),
CD11c (N418), and F4/80 (BM8) were purchased from eBioscience. TNF4α (MP6-XT22,
554419) and Ab 2.4G2 anti-FcγIII/II (553141) purchased from BD Biosciences. Albumin antibody (ab19196) was purchased from Abcam. GAPDH antibody (Millipore, AB2302, Temecula,
CA) was purchased from Sigma-Aldrich. Human TNF-α ELISA kit (EH3TNFA, Kalamazoo,
MI), Human IL-6 ELISA kit (EH2IL6, Kalamazoo, MI), and Human IFN-γ kit (EHIFNG, Kalamazoo, MI), Alexa Fluor 568 phalloidin (A12380), Hanks' Balanced Salt Solution (HBSS,
88284), Cytoseal XYL (94265), Hematoxylin 2, Maxima first strand cDNA synthesis kit
(K1672), Maxima SYBR green/Rox (6-carboxyl-X-rhodamine) quantitative PCR Master Mix
(K0221), and fixable Aqua Live/Dead cell staining kit (L34960) were purchased from Thermo
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Fisher Scientific. Poly lactic acid (PLA, P1691-5G), polyethyleneimine (PEI, low molecular
weight, Typical Mn 1800, Typical Mw 2000, 408700-250), WST-1 (11644807001), lipopolysaccharides (LPS, L7770), DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride, D9542) Oil Red
O (O0625) isopropanol (190764), primers, and collagenase VIII (C2139) were purchased from
Sigma-Aldrich. 10% fat control diet and 60% fat diet were purchased from Research DIets (Research Diets, Inc, D12450B, New Brunswick, NJ). Polyvinyl alcohol (PVA, Stock #41238, 8689% hydrolyzed low molecular weight) was purchased from Alfa Aesar. DMEM/Ham's F-12
medium was purchased from Invitrogen (Grand Island, NY). Penicillin and streptomycin (100X
Corning) was purchased from Corning. Heat-inactivated fetal calf serum (10%, v/v) was purchased from Atlanta Biologicals (Atlanta, GA). Four-chamber tissue culture glass slides were
purchased from BD Falcon (Bedford, MA, USA). Eosin Y Solution (Modified Alcoholic) was
purchased from Scytek (EYB500, Logan, Utah). RNeasy Plus Mini Kit was purchased from Qiagen (Valencia, USA) and DNase I was purchased from Roche Diagnostics (Indianapolis, IN).
2.2.2

NPs fabrication

The NPs are fabricated using the double emulsion method which is usually referred to the
W1/O/W2 emulsion. Twenty-nine μL of 5 μM CD98 siRNA is stabilized with 18 μL of 5mM
polyethyleneimine (PEI) to achieve an N/P ratio of about 30 (N stands for the ammonium charge
and the P stands for the phosphorous charges). The mixture is incubated at room temperature for
10 min to form the polyplex. The internal phase is formed by adding 750 μL of 50g/L BSA into
the polyplex solution with a gentle mix. The PLA is dissolved in the dichloromethane (DCM) to
make the stock with a concentration of 20 g/L. The internal phase is mixed with poly lactic acid
(PLA) to make W1/O emulsion (first emulsion) after 1 min of ultrasonication with 50% active
cycles at 70% power (Digital Sonifier 450, Branson, Danbury, CT) with the ice. Then the first
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emulsion is added into the 0.3 g/L of polyvinyl alcohol (PVA) solution to form the W1/O/W2
emulsion. Then, the W1/O/W2 emulsion was added into the PVA solution (0.1g/L) with stirring
and NPs will form during the evaporation of DCM. The NPs are centrifuged down at 9953 g for
1 h. And the pellets were rinsed 3 times and the samples were lyophilized after resuspension. The
dried power was weighted and stored at -80 degree for further treatment usage and characterization.
For the fabrication of scramble siRNA NPs or the FITC-labelled siRNA loaded NPs, the
same procedure was used, with replacing the cargoes from CD98 siRNA to the scramble siRNA
or the FITC-labelled siRNA.
2.2.3

NPs size and zeta potential measurement

The size of NPs (diameter) is measured by light scattering (90Plus/BI-MAS, Brookhaven
Instruments Corporation, Holtsville, NY). The zeta potential of NPs is measured in the zeta potential analyzer (ZetaPlus, Brookhaven Instruments Corporation, Holtsville, NY) by accessing
the light scattering under an electric field. All the results were obtained from 3 measurements
and each measurement is repeated 10 times.
2.2.4

SEM measurement

A drop of NPs solution is added onto a glass coverslip. After the samples were dried in
room temperature, samples were sputter-coated with Au/Pd (Denton desktop sputter coater,
Moorestown, NJ). The images were obtained using LEO 1450VP (New York, NY).
2.2.5

AFM measurement

A drop of NPs solution is added onto mica slides and the samples were dried in a hood at
room temperature. The images were obtained using a SPA 400 AFM (Seiko Instruments Inc.,
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Japan) with the following settings: 1) trapping mode with 150 kHz resonant frequency and 2)
scanning frequency of 1 Hz.
2.2.6

Cytotoxicity assay (WST-1)

Even though the cytotoxicity of PLA is not a concern, the off-target effects of siRNA
might cause cell death. To access the potential cytotoxicity of the CD98 siRNA NPs, the cell
proliferation reagent, WST-1, is used. The cells were seeded on a 96-well plate with 5 × 104 cells
per well and NPs were added into the culture medium at the final concentration of 1 mg/mL. After incubation, 10 µL of WST-1 reagent was added into the medium and the live cells will convert the WST-1 to form the purple formazan. The A440 was read by a plate reader and the viability in cells without any treatment was set to 1 (control).
2.2.7

Cell culture

Hep G2 (HepG2) cells, Caco2-BBe cells, and Raw264.7 cells were culture in the 37 °C
incubator with 5% of CO2 (v/v) in a humidified atmosphere. The culture medium used was
DMEM/Ham’s F-12 medium (Invitrogen, Grand Island, NY) with 10% (v/v) of heat-inactivated
fetal calf serum, 1% of penicillin/streptomycin, and 2 mM of L-glutamine.
The Lipopolysaccharides (LPS) stimulation is done by adding the LPS into the culture
medium for 24 h with the final concentration of 10 µg/mL.
2.2.8

NPs internalization studies

To track the NPs, the FITC-labeled siRNA was used to make the NPs. Thus, the signal of
FITC inside of the NPs can be seen by using fluorescence microscopy. In this study, fluorescence microscopy was used to visualize the NPs. The internalization was studied both in vitro
and in vivo.

34
For in vitro internalization study, the HepG2 cells were seeded in chamber tissue culture
slides (BD Falcon, Bedford, MA, USA). Cells were incubated with 200 µg/mL of FITC-labeled
siRNA-loaded NPs overnight. Then the medium was removed, and cells were rinsed with PBS
for 3 times to remove the free NPs outside of cells. The cell samples were fixed with 4 % paraformaldehyde (PFA) at room temperature for 20 min in dark. The slide was sealed by the prolong golden reagent with DAPI.
For in vivo internalization study, mice were sacrificed 4 h after the tail intravenous injection of FITC-labeled siRNA-loaded NPs. The major tissues were collected and treated properly
for the next staining. The actin was stained by phalloidin with Alexa Fluor 568 (1: 60 diluted) for
45 min, and the nuclei were stained by DAPI for 5 min.
2.2.9

Mice experiment

All the mice experiments were approved by Georgia State University Institutional Animal Care and Use Committee (protocol number A13041).
C57BL/6 female mice (8 weeks of age) were purchased from the Jackson Laboratory and
group-housed (5 mice per case) with the following condition: 25 °C, a 12 to 12 hours light-dark
cycle, and allowed unrestricted access to potables and standard mouse chow.
The NAFLD model is built by feeding C57BL/6 mice with a 60% fat diet (high-fat diet,
HFD). The control group mice were fed with a 10% fat diet (noted as the low-fat diet, LFD).
Mice will receive a dose of NPs (CD98 siRNA-loaded NPs or the scrambled siRNA-loaded NPs)
biweekly.
2.2.10 Oil red staining
The stock solution of 0.5% (w/v) Oil Red O is prepared by dissolving 0.5 g of Oil Red O
in 100 mL of isopropanol. Before staining, the tissues are rinsed under the running water for 10
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min and next, rinsed with 60% of isopropanol. Next, the slides were merged in the Oil Red O
working better for 15 min. Hematoxylin 2 was used to stain the nuclei on the slides. Then, slides
were rinsed with water and drying in the air. The slide was sealed by using a drop of cytoseal
XYL reagent with a cover glass slide.
2.2.11 Hematoxylin and Eosin Y (H&E) staining
Before the staining, the paraffin-embedded tissues were dewaxed by the following procedures: 10 min of xylene wash for twice, 1 min of 100% ethanol wash for twice, 1 min of 95%
ethanol wash for twice, and 1 min of 75% ethanol wash for twice. The dewaxed slides were
stained with Hematoxylin for 5 min and followed by washing with DI water. The bluing reagent
is used to enhance the color of nuclei. After the second rinse with DI water, the slides were
rinsed with 100% ethanol before dipping into the Eosin Y solution. In the end, the excessive Eosin Y was removed by 100% ethanol washes and dry in the air. The slides were sealed using the
cytoseal XYL reagent with a cover slide.
2.2.12 Liver grade calculation
The H&E stains were used to count the grade for liver damages by using the method reported by Kleiner et al.[185] The grading system is adding the scores from three subsystems: i.e.,
steatosis, lobular inflammation, and hepatocytes ballooning. The scores for steatosis and lobular
inflammation were ranged from 0-3 and the score for hepatocyte ballooning was ranged from 02. The total scores were the sum of the scores in three subsystems, which is called the NAFLD
activity score (NAS).
2.2.13 RT-qPCR
The total RNA was isolated from cells by using the RNeasy Plus Mini Kit under the manufacturer’s instructions. The quality of yield RNA was examined by checking the A260/A280

36
using a plate reader. The cDNA was synthesized for the same amount of total RNAs by using
Maxima first strand cDNA synthesis kit. The expression level of certain mRNA is accessed by
using the Maxima SYBR green (6-carboxyl-X-rhodamine) quantitative PCR Master Mix. The
expression level of mRNA in the control group was set to 1 and the changing fold in the mRNA
was calculated by a 2-ΔΔCT method. The sequence of primer was listed in table 1 in Appendix.
2.2.14 Western blot
The liver samples from mice with CD98 siRNA-loaded PLA NPs or the scramble
siRNA-loaded NPs were homogenized with RIPA buffer to obtain the total proteins. 100 µg of
total protein was loaded into the 12% SDS-PAGE gel. The membrane was blocked with 5% nonfat milk and then applied with the primary antibodies for 2 h at room temperature. Next, the
membrane was washed 15 min for 3 times and applied with a secondary antibody with HRP conjugation (1: 4000 diluted). The films were developed by using a SERIES 2000A Processor film
developer. The primary antibodies used in this studies are listed below: NF Kappa β (Santa
Cruz,sc-9160, Dallas, TX), GAPDH (Millipore, AB2302, Temecula, CA) , and CD-98 (Santa
Cruz, sc-9160, Dallas, TX).
2.2.15 ELISA for cytokines assay
HepG2 cells were culture with CD98 siRNA-loaded NPs for 12 h with or without LPS
stimulation. The culture medium was collected for ELISA assay. Human TNF-α ELISA Kit, human IL-6 ELISA Kit, and human IFN-γ ELISA Kit were used to measure the cytokines secreted
by the HepG2 cells. The cytokine secretion amounts in HepG2 cells without any treatment (no
LPS, no NPs) were used as the control.
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2.2.16 Flow cytometry
The liver samples were cut into small pieces and incubated in the HBSS with 5% FBS,
1.5 mg/mL of collagenase VIII, and 40 U/mL DNase I at 37 °C for 11 min in a shaker. Next, the
solution was filtered by a 100 µm strainer to remove big particles and centrifuged at 300 g to get
the cell pellets. The obtained cells were suspended in the PBS solution with 5% of FBS, and perform the live/death staining and antibody staining (4°C, 30 min). Flow cytometry analysis was
performed using the LSR II.
2.2.17 Statistical analysis
Statistical analysis was performed using unpaired two-tailed Student's t-test by GraphPad
software (v3.06). Values were expressed as means ± SEM from experiments performed in triplicate (n = 3), except for cytotoxicity tests and in vivo experiments (respectively n = 8 and n=5).
Data are representative of n determinations. ***P < 0.001, **P < 0.01, *P < 0.05, and NS, not
statically significant.
Results
2.3.1

Characterization of CD98 siRNA-loaded poly lactic acid (PLA) NPs

CD98 siRNA-loaded NPs were fabricated by using the double emulsion method, the size,
and zeta potential of CD98 siRNA-loaded NPs or scramble siRNA-loaded NPs were detected by
DLS, SEM, and AFM. As seen in Figure 2.1 A and B, the average size of CD98 siRNA-loaded
NPs is about 273 nm with a zeta potential of -12.84 mV. The average size of scramble siRNAloaded NPs is about 274 nm with a zeta potential of -15.60 mV. The SEM (Figure 2.1 C) and
AFM (Appendix Figure 5-0.1) confirmed the shape of NPs was spherical with a size close to 280
nm in diameter.
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Figure 2.1: The characterization of CD98 siRNA-loaded NPs.
(A) Average size and (B) zeta potential (mV) of CD98 siRNA-loaded NPs and scrambled siRNAloaded NPs were measured by light scattering analysis (values represent means ± SEM. Data are
representative of n=3 determinations). (C) Scanning electronic microscopy image of CD98
siRNA-loaded NPs (The sample was prepared using a drop of NPs at a concentration of
500 μg/mL). (D) Cytotoxicity of 1 mg/mL CD98 siRNA-loaded NPs and scrambled siRNAloaded NPs on HepG2 cells after 48h (values represent means ± SEM. Data are representative of
n=8 determinations). (E) Kinetic of the release of CD98 siRNA complexed with PEI form NPs
(PBS buffer, 37°C), the x-axis represents the log10 (Time).[171]
The drug release profile may affect the therapeutic effects.[186] As shown in Figure 2.1
E, the FITC-label siRNA accumulated release amount was plot versus the dialysis time. Within
the beginning of 4 h, about 40% of the drug was released. This indicated the burst effects which
refers to a large number of cargoes release from NPs at the beginning within a short period, were
not observed in this formulation.[187] The further study indicated 4 h is enough for large
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amounts of NPs to accumulate in the liver, thus, some of the 40% of siRNA can be released inside the cytosol. And the PEI/siRNA complex also contributes to the sustainable drug release inside cytosol (for the rest 60% siRNA). The result of CD98 siRNA-loaded NPs or scramble
siRNA-loaded NPs cytotoxicity on HepG2 cells was showed in Figure 2.1 D.
No cytotoxicity was found in CD98 siRNA-loaded NPs (96.16%, 1 mg/mL) or scramble
siRNA-loaded NPs (98.56%, 1 mg/mL) treated HepG2 cells for 72 h.
2.3.2

In vitro internalization of CD98 siRNA-loaded NPs

The internalization efficiency of NPs will affect the therapeutic outcomes. As seen in Appendix 5-0-2, the bright signals on the membrane and cytosol indicted the presence of FITC-label siRNA during the endocytosis and inside of cytosol. To test whether the CD98 siRNA could
degrade the CD98 mRNA in the cells, the CD98 mRNA expression levels in different cell lines
with or without LPS stimulation were accessed by using RT-qPCR. As shown in Figure 2.2,
when compared to the CD98 expression level in the control group, the LPS increased the CD98
mRNA expression level significantly in the scramble siRNA-loaded NPs treated group. And the
pre-treatment of CD98 siRNA-loaded NPs decreased the CD98 mRNA expression level in
HepG2 cells, Raw264.7 cells, and Caco2-BBe cells for 6-, 7-, 8-times respectively when compared with the CD98 expression level in scramble siRNA-loaded NPs treated group. The significant decrease in the CD98 mRNA level with applying CD98 siRNA-loaded NPs further indicated the NPs could be taken by the cells with a high efficiency.
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Figure 2.2: CD98 mRNA expression level was decreased after the incubation with CD98
siRNA-loaded NPs.
CD98 mRNA expression levels in three different cell lines (A) Raw 264.7, (B) Caco2 BBe, and
HepG2 cells with different treatments were studied using the RT-qPCR. The cell without LPSstimulation and NPs treatment were used as the control. The LPS-stimulated cells with CD98
siRNA-loaded NPs were showed with the legend in + LPS + CD98 siRNA NPs. The LPS-stimulated cells with scrambled siRNA-loaded NPs were showed with the legend in + LPS + scrambled siRNA NPs. The LPS stimulation was incubating cells with 10 µg/mL LPS for 24h. The
NPs concentration for treatment is 200 µg/mL. Values represent means ± SE. Data are representative of n=3 determinations. ***P < 0.001, **P < 0.01, *P < 0.05, and NS, not statically significant.[171]
2.3.3

CD98 siRNA-loaded NPs inhibited the expression of the pro-inflammatory
cytokines

As demonstrated in the literature, the CD98 has shown a pro-inflammatory effect. In this
study, the mRNA expression level of IFN-γ, COX-2, and TNF-α were measured (Figure 2.3).
Pre-treatment with scramble siRNA-loaded NPs in three cell lines showed an increased expression level of those cytokines with the LPS stimulation. While pre-treatment of CD98 siRNAloaded NPs decreased the LPS-induced cytokine mRNAs expression. Pre-treatment of CD98
siRNA-loaded NPs decreased the TNF-α mRNA expression level in HepG2 cells, Raw264.7
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cells, and Caco2-BBe cells for 10-, 90-, 10-times respectively when compared with the CD98 expression level in scramble siRNA-loaded NPs treated group (Figure 2.3 A-C). Pre-treatment of
CD98 siRNA-loaded NPs decreased the COX-2 mRNA expression level in HepG2 cells,
Raw264.7 cells, and Caco2-BBe cells for 4-, 5-, 5-times respectively when compared with the
CD98 expression level in scramble siRNA-loaded NPs treated group (Figure 2.3 D-F). Pre-treatment of CD98 siRNA-loaded NPs decreased the IFN-γ mRNA expression level in HepG2 cells,
Raw264.7 cells, and Caco2-BBe cells for 6-, 10-, 2-times respectively when compared with the
CD98 expression level in scramble siRNA-loaded NPs treated group (Figure 2.3 G-I).

Figure 2.3: CD98 siRNA-loaded NPs treatments decrease the expression of pro-inflammatory cytokines.
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TNF-α, COX-2, and IFN-γ mRNA expression levels in three different cell lines (A) Raw 264.7,
(B) Caco2 BBe, and HepG2 cells with different treatments were studied using the RT-qPCR. The
cell without LPS-stimulation and NPs treatment were used as the control. The LPS-stimulated
cells with CD98 siRNA-loaded NPs were showed with the legend in + LPS + CD98 siRNA NPs.
The LPS-stimulated cells with scrambled siRNA-loaded NPs were showed with the legend in +
LPS + scrambled siRNA NPs. The LPS stimulation was incubating cells with 10 µg/mL LPS for
24 h. The NPs concentration for treatment is 200 µg/mL. Values represent means ± SEM. Data
are representative of n=3 determinations. ***P < 0.001, **P < 0.01, *P < 0.05, and NS, not statically significant.[171]
The expression of the secreted cytokines was also studied by using the corresponding
ELISA assays. As shown in Figure 2.4, the uptake of CD98 siRNA-loaded NPs decreased the expression levels of TNF-α (14% decrease, p<0.05), IL-6 (6% decrease, NS), and IFN-γ (500% decrease, p<0.001) when compared to the control group.

Figure 2.4: CD98 siRNA-loaded NPs inhibited the secretion of LPS-induced pro-inflammatory cytokines, TNF-α, IL-6, and IFN-γ.
(A) TNF-α, (B) IL-6, and (C) IFN-γ expression levels in LPS-stimulated HepG2 cells with or
without the treatment of CD98 siRNA-loaded NPs. The LPS stimulation was incubating cells
with 10 µg/mL LPS for 24 h. The NPs concentration for treatment is 200 µg/mL. Values
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represent means ± SEM. Data are representative of n=3 determinations. ***P < 0.001, **P <
0.01, *P < 0.05, and NS, not statically significant.[171]
Taken together, the CD98 siRNA-loaded NPs showed a strong CD98 silence effect and
the potential in anti-inflammatory. As mentioned, the inflammatory could be the major driving
force in the NAFLD development. Therefore, the NAFLD mice were used to evaluate the therapeutic effects of CD98 siRNA-loaded NPs.
2.3.4

CD98 siRNA-loaded NPs are accumulated in the liver

The FITC-labeled siRNA NPs were used for NPs biodistribution in major organs including heart, lung, brain, colon, kidney, spleen, and the liver. The biodistribution of NPs in both
HFD mice and LFD mice was studied and the signal of FITC was only found in the kidney,
spleen, and liver after the tail vein injection.
As shown in Appendix Figure 5-0.3, the kidney, spleen, and liver from the HFD mice
without treatment of FITC-labeled siRNA NPs were used to control the autofluorescence. The
red signals indicated the actin, and the blue signals indicated the nuclei. In LFD mice, no strong
signal of FITC was found in the spleen (Figure 2.5 C), and slightly intensity of FITC signals was
found in the liver (Figure 2.5 E), and kidney (Figure 2.5 A). However, the biodistribution profiles in HFD mice showed the huge difference when compared with those in LFD mice. The fluorescent signal was found in Figure 2.5 show in the yellow color which indicated the overlapping
of FITC-labeled siRNA NPs and the actin. A clear intensity of FITC was found in the spleen
(Figure 2.5 D) which was not obviously seen in the spleen of LFD mice. In HFD mice, the kidney (Figure 2.5 B) and liver (Figure 2.5 F) showed a stronger accumulation of FITC-labeled
siRNA NPs when compared spleen. Those results implied the HFD might cause changes in the
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spleen. As known, the spleen plays important role in the immune responses and the changes in
the spleen might be involved in the NAFLD.

Figure 2.5: Biodistribution of NPs in mice at 4 h after the i.v. the administration indicated
the liver in HFD group uptake most of NPs.
Among the major organs, the signal of FITC was only found in the kidney (A&B), spleen
(C&D), and liver (E&F). The FITC-labeled siRNA-loaded NPs (green) was used to track the
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presence of NPs. The actin was stained with Alexa Fluor 568 conjugated phalloidin (red) and
DAPI was used to stained the nuclei (blue). The scale bar is 50 µm.

2.3.5

The NPs are specifically accumulated in macrophages-like cells and hepatocytes

As mentioned, different cells in the liver played different roles in NAFLD. Thus, the biodistribution of NPs inside the liver was measured. As shown in Figure 2.6, the upper panel is the
biodistribution profiles derived from HFD mice and the lower panel is the biodistribution profiles derived from LFD mice. When compared the column B, C, and D, the percentages of FITCpositive (NP-positive) macrophages-like cells, dendrite cell, and hepatocytes in HFD mice is 2.2fold, 0.95-, and 1.68-fold higher than that in the LFD mice, respectively. This is the same as
what we found in the whole body biodistribution study, that more NPs accumulation was found
in the HFD mice than that in LFD mice. In the liver, hepatocytes and macrophages-like cells uptake most of the NPs. A very limited amount of uptake percentage was found in the dendrite
cells.
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Figure 2.6: The biodistribution of NPs inside of the liver at 4 h after the i.v. administration
indicated the NPs are majorly taken by Kupffer cells and hepatocytes.
Representative FACS plots showing the percentage of FITC-positive cells in each cell populations, including (A) live cells, (B) macro-phages like cells, (C) dendritic cells, and (D) hepatocytes in HFD mice (upper panel) or LFD mice (lower panel) after administration of FITC-labeled
siRNA-loaded NPs. Cells were gated as followed: hepatocytes (CD45-MHC class II- F4/80CD11b-CD11c-albumin+), macrophages-like cells (CD45+MHC class
II+F4/80+CD11b+CD11c-), and dendritic cells (CD45+MHC class II+F4/80-CD11b+CD11c+).
Values represent means ± SEM. Data are representative of n=5 mice per group. **P < 0.01, *P <
0.05 and NS, not statically significant.[171]
2.3.6

The CD98 expression level was decreased after delivery of CD98 siRNA
loaded NPs

After a large amount of FITC-labeled-siRNA-loaded NPs found in the liver, the expression level of CD98 protein in live was accessed by western blot. As seen in Figure 2.7, the injection of CD98 siRNA-loaded NPs decreased the CD98 expression. Quantification results
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indicated the CD98 siRNA-loaded NPs can reduce CD98 expression by about 90%. The expression of NF-κB was decreased after the CD98 siRNA-loaded NPs administration indicated the
NF-κB is likely among one of the downstream targets of CD98 signaling pathway.

Figure 2.7: CD98 siRNA-loaded NPs silenced the CD98 protein expression level in the liver.
CD98 and NF-κB expression levels in HFD mice livers were examined by the western blot after
treated with CD98 siRNA-loaded NPs or scrambled siRNA-loaded NPs twice a week. The dose
of NPs is 500 µg of NPs per mice.[171]
2.3.7

CD98 siRNA-loaded NPs alleviated the NAFLD symptoms

As seen in Figure 2.8, the serum level of ALT in HFD mice with CD98 siRNA-loaded
NPs treatment was significantly lower (about 45%, p< 0.01) than that in the HFD mice with
scramble siRNA-loaded NPs. The serum level of ALT in HFD mice with CD98 siRNA-loaded
NPs treated groups was close to that in the mice with a regular diet (healthy mice, Figure 2.8 A).
The amount of cholesterol (Figure 2.8 B), triglycerides (Figure 2.8 E), and glucose (Figure 2.8
C) in CD98 siRNA-loaded NPs treated HFD mice were significantly decreased when compared
with those in scramble siRNA-loaded NPs treated groups. The HDLc in CD98 siRNA-loaded
NPs treated HFD mice was slightly decreased (NS) when compared with that in scramble
siRNA-loaded NPs treated groups (Figure 2.8 D).
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Figure 2.8: CD98 siRNA-loaded NPs decreased the pro-steatosis markers in NAFLD mice.
The pro-steatosis makers including the (A) serum ALT, (B) cholesterol, (C) glucose, (D) HDLc,
and (E) triglycerides are analyzed in mice with different diets (HFD or regular diet) and received
different treatments (CD98 siRNA-loaded NPs or scrambled siRNA-loaded NPs biweekly. The
dose for each treatment was 500 µg of NPs. Values represent means ± SEM, n= 5. **P < 0.01,
*P < 0.05, and NS, not statically significant.[171]
Since the biopsy is the golden standard for NAFLD diagnosis, the image of the liver was
visualized by Sirius red and H&E stains (Figure 2.9).[188] Clear lipid vacuoles (Figure 2.9 B)
and the collagens (Figure 2.9 A) are seen in the liver from HFD with scramble siRNA-loaded
NPs treatment. While no collagen (Figure 2.9 C) or the lipid vacuoles (Figure 2.9 D) was found
in the liver from HFD mice with CD98 siRNA-loaded NPs treatment. The total NAFLD Activity
Score (NAS) in HFD mice with scramble siRNA-loaded NPs treatment is 7 which indicates a serious level of liver damage (Figure 2.9 E). While the NAS equals zero in the CD98 siRNAloaded NPs treated HFD mice indicated the liver is under healthy condition.[185]

49

Figure 2.9: CD98 siRNA-loaded NPs significantly improved HFD-caused liver damages.
Sirius Red stains showed the fibrotic collagens in the HFD mice received CD98 siRNA-loaded
NPs (C) or scrambled siRNA-loaded NPs (A) twice a week. The H&E stains showed the hallmark of NAFLD (lipid vacuolization) in the HFD mice CD98 siRNA-loaded NPs (D) or scrambled siRNA-loaded NPs (B) twice a week. Each group contains 5 mice. The scale bar is 50 µm.
(E) The NAFLD activity scores were calculated based on the methods reported by Kleiner.[171,
185]
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Discussion
CD98 is more than just an amino acid transporter.[14, 81, 104, 115, 116] The CD98 has
been well identified as the marker and promoter protein in inflammatory disease including colitis
and IBD. In the colitis, the upregulation of CD98 was found as well as the upregulation of proinflammatory cytokines such as TNF-α, IFN-γ, IL-1β, and IL-6.[182, 189, 190] And silencing of
CD98 by delivery in the CD98 siRNA into the gastrointestinal site showed a decreased level of
pro-inflammatory cytokines.[132] In the liver, the pro-inflammatory cytokines have shown the
ability in promoting NAFLD development. According to the most accepted NAFLD pathogenesis theory (multiple hit theory), the stresses such as nutrients and the inflammation showed a high
impact on the NAFLD developments.[191] For example, the most-well studied pro-inflammatory
cytokine in NAFLD, TNF-α, is highly correlated with fibrosis level in NASH patients and liver
damages (NAS) in NAFLD. But no significant improvement was found in the clinical trial by using an anti-TNF-α reagent, pentoxifylline, for NAFLD or NASH treatment. The failure of this
trial might be caused by a single type of cytokines is not enough for the treatment of NAFLD,
since many types of cytokines are involved in the development of NAFLD. Also, without specific targeting ability, the side effects of immune-related diseases might impair the application of
this anti-TNF-α reagent.[192]
The targeting delivery feature of NPs allowed most drugs accumulated in the lesion or the
lesion-related sites. Thus, enhancing the therapeutic effects by the high presence of the drug in
the lesion and decrease the side effects on other tissues.[193] Decreased CD98 expression in the
liver specifically decrease serval pro-inflammatory cytokines expression, leading to the NAFLD
alleviation. In addition, the CD98 siRNA reduced expression level of NF-κB, leading to the shutdown of pro-inflammatory cytokines productions.[194]
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The average size of CD98 siRNA-loaded NPs is around 270 nm. The SEM image indicated the some CD98 siRNA-loaded NPs were less than 150 nm while some are larger than 300
nm. The size and surface modifications will affect the biodistribution of NPs inside of the liver.
The Kupffer cells are preferring the NPs with sizes bigger than 200 nm while only small NPs
(smaller than 150 nm) can pass the LESCs barriers to target the hepatocytes. Also, the hydroxyl
group on the surface of NPs helps reduce the clearance by macrophages. Decreased the CD98
expression in macrophage-like cells showed a significant decrease in pro-inflammatory secretion. The Kupffer cells are the macrophages inside the liver. Targeting the Kupffer cells and
hepatocytes at the same time could show strong therapeutic effects on NAFLD since different
types of cells (hepatocytes, stellate cells, Kupffer cells, etc.) were involved in NAFLD progression.
In conclusion, CD98 can be a potential therapeutic target for NAFLD treatment, and the
NPs can be an effective way in delivering the CD98 siRNA to the liver. And more studies on the
formulations are required to improve the drug targeting delivery to different hepatic cells, which
can help us to find out the most effective way in curing the NAFLD via targeting CD98 or other
molecules.
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THE INTERNALIZATION OF GARLIC-DERIVED NANOVESICLES ON LIVER
CELLS IS TRIGGERED BY INTERACTION WITH CD98
Background
Recently, plant-derived nanovesicles were isolated from several edible plants such as grape-

fruits, gingers, carrots, apples, and lemons.[7-10] Those plant-derived nanovesicles resembled
their mammalian exosome counterparts in that they carried functional cargos such as small molecules, proteins, mRNA, and miRNA which can modulate the fate of recipient cells.[15] Several
plant-derived nanovesicles have been reported to be effectively used for cancer therapy, changing
the gut microbiota composition, and protecting mice from DSS-induced colitis and inflammatory
bowel disease.[9, 11, 15] These reports indicate that plant-derived nanovesicles are involved in
interspecies communication for their biological effect.[7] Although plant-derived nanovesicles are
promising in anti-inflammatory and cancer therapy, the uptake mechanism of the plant-derived
nanovesicles has yet to be determined.
Understanding the mechanisms of the mammalian exosomes can elucidate potential mechanisms of plant-derived nanovesicles. The main uptake mechanisms for mammalian exosomes include phagocytosis, clathrin-dependent, or clathrin-independent pathways.[18, 19, 195] Heparan
sulfate proteoglycans (HSPG) on cell surfaces could be a possible receptor for exosome endocytosis, but it has been reported that the HSPG on the surface of exosomes is not involved in the
internalization of exosomes.[20] Another study revealed that fibronectins on the surface of myeloma cell-derived exosomes have interactions with HSPG on target cells.[21] Also, proteins on
both the surface of ovarian cancer cell-derived exosomes and ovarian cancer cells are important
for uptake.[22]
CD98 is a transmembrane, glycoprotein heterodimer, consists of the CD98 heavy chain
(CD98hc) and several light chains (CD98lc), such as large amino acid transporter 1 (LAT 1).[104]
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The glycan on CD98hc consists of tetra-antennary with terminal fucosylation and mannose oligosaccharides (oligomannose).[104, 196] CD98 has various functions which include mediating cell
proliferation through activating the integrin-β pathway, importing amino acid to support cell
growth, and regulating cell fusion in several types of cell lines (BeWo cells, Peripheral blood
mononuclear cells, and L929 cells).[104, 197, 198] CD98 has been reported to play an important
role in the internalization of human β-defensin 3 and endocytosis of mature vaccinia virus particles. Recently, a study has shown that the LAT 1 may be involved in the uptake of nanoparticles.[106, 113, 116] CD98 was used as a targeted protein to enhance the internalization of therapeutic nanoparticles due to its overexpression in tumor and inflammatory tissues.[114] These reports indicate that CD98 played an important role in the uptake process. CD98 has also been linked
to inflammatory bowel disease (IBD) and plays a potential role in chronic liver disease, e.g., nonalcoholic fatty liver disease (NAFLD).[129] Thus, CD98 can be a promising target for both therapeutic and drug delivery.
Lectin, a type of protein with a specific binding affinity to saccharides, plays an important
role in interspecies recognition. For example, the innate immune recognition of coronaviruses was
mediated by the interaction of certain lectins on cell membranes and the oligomannose from coronaviruses.[199] A lectin from Sparassis latifolia (a mushroom) has shown antibacterial activity
against E. coli and other drug-resistant strains.[200] Inspired by those lectin-carbohydrates mediated interspecies communications, it is hypothesized that the interactions between plant-derived
nanovesicles and mammalian cells are mediated by the interaction of lectins and saccharides.
Several dietary lectins have been found to exert health benefits through the induction of
apoptosis after binding to the membrane. Among various edible plants, garlic is enriched in the
lectins (1 mg of lectins per 1 g of garlic)[201] and has well-documented health benefits in many
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epidemiology studies.[202, 203] In this study, the HepG2 cell line has been shown the internalization of garlic-derived nanovesicles (GDVs). The GDVs were isolated by the differential centrifugation method. And the resultant GDVs were identified by size, zeta potential, and morphology
of previous studies.[7, 9, 11, 204] Surface proteins from GDVs were removed by incubation of
GDVs with trypsin, and internalization properties were examined in HepG2 cells over various time
points leading to the finding that the surface proteins from GDVs were involved in the internalization. Mass spectrum-based protein identification indicated that a mannose-specific binding lectin (II Lectin) is located on the surface of GDVs. Saturation of the II lectins with mannose and
blocking CD98 receptors with CD98 antibody significantly impairs the GDV internalization. In
addition, co-localization between GDVs and CD98 reduces significantly after trypsin digestion of
GDVs’ the surface protein. Taken together, those results indicate both proteins in the surface of
GDVs (majorly II Lectin) and CD98 from cell membranes have directly interacted during the internalization of GDVs. The undigested GDVs treated group showed stronger in vitro anti-inflammatory effects when compared to the digested GDVs due to the changes in GDV uptake. This
study contributed to understanding a part of the interspecies communication and provided new
angles in understanding the benefit of dietary garlic.
Methods
3.2.1

Cell culture

HepG2 cell lines were cultured in the 1 g/L L-glutamine DMEM medium with 10% FBS,
5% penicillin, and streptomycin (100X Corning) at 5% CO2 and 37°C. LPS stimulation was conducted by adding 10 µg/mL of LPS into the culture medium for 24 h.[171] CD98 siRNA specific
downregulation was performed following oligofectamine transfection procedure. Briefly, a serumfree medium (SFM) was gently mixed with oligofectamine and let for incubation at room
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temperature for 5 min. The diluted CD98 siRNA were combined with the Oligofectamine/SFM
mix and incubated for 15 min at room temperature to form a complex. The complex was then
added into cells for a 4h-incubation at 37°C (the final concentration of siRNA is 100 nM). After
the 4h-incubation, the reaction was completed by adding concentrated FBS to reach a final concentration of 10% of FBS in the medium.
3.2.2

Isolation of the Garlic-derived Nanovesicles (GDVs)

Garlic was washed 3 times with 1X PBS buffer and then homogenized using a blender with
refrigerated PBS (4°C). The collected juice was centrifuged according to a multistep procedure
optimized in our laboratory to get GDVs. The mixture was centrifuged at 5,000g for 20 min 3
times, 10,000 g for 1 h, and centrifuged at 120,000 g for 70 min. The pellet was washed with cold
PBS 3 times and resuspended in PBS. The size was detected using the dynamic light scattering
(DLS) method, atomic force microscope (AFM), and transmission electron microscopy (TEM).
The zeta potential was measured by Malvern Nano ZS90.
3.2.3

Digest the surface protein of GDVs

The concentration of the GDVs was calculated by the total protein concentration using the
DC assay (BIO-RAD, Hercules, CA). GDVs were incubated with trypsin (0.25%, Corning) at a
mass ratio of 2:1 at 37°C for 1, 2, 3, 4h. After digestion, the pellets were collected by ultracentrifugation at 120,000 ×g for 2 hours. The pellets were washed with cold PBS 3 times and resuspended
with 1X PBS and labeled as T1, T2, T3, and T4 GDVs respectively for 1h, 2h, 3h, and 4h of
enzymatic digestion.
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3.2.4

TEM measurement

A drop of the sample (10 μg of protein) was deposited onto the surface of a formvar-coated
copper grid, after which 1% uranyl acetate was added and the sample was drying at room temperature for further imaging.
3.2.5

AFM Measurement

A drop of the sample (10 μg of protein) was deposited onto a freshly cleaved mica slide
and drying in a cleaning vacuum hood with a cover at room temperature. AFM images were acquired using a SPA 400 AFM instrument (Seiko Instruments Inc., Chiba, Japan).
3.2.6

In-gel digestion and MS experiments

The concentration of the GDVs was calculated by the total protein concentration using the
DC assay (BIO-RAD, Hercules, CA). GDVs were incubated with trypsin (0.25%, Corning) at a
mass ratio of 2:1 at 37°C for 1, 2, 3, 4h. After digestion, the pellets were collected by ultracentrifugation at 120,000 ×g for 2 hours. The pellets were washed with cold PBS 3 times and resuspended
with 1X PBS and labeled as T1, T2, T3, and T4 GDVs respectively for 1h, 2h, 3h, and 4h of
enzymatic digestion.
After ultracentrifugation, GDVs were lysis in RIPA buffer for protein extraction. The gel
was run and then stained using Denville protein blue stain. The gel was microwaved first with the
250 mL of DI water for 3min twice, then microwaved with 50 mL of Denville protein blue stain
solution for 2 min, another 2 min in 250 mL of DI water.
The in-gel digestion was conducted by the method described previously.[205] Gel spots
were picked from the 1 D gel and rinsed with double distilled water for 3 times. The spots were
washing with 400 µl of 25 mM ammonium bicarbonate/methanol for 1 min. The destaining of
Coomassie Blue was conducted by incubating the gel spots in 400 µl of 25 mM ammonium
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bicarbonate/acetonitrile for 5 min and 100% acetonitrile for 1 min, respectively. The acetonitrile
was removed and gels were dried via speed-vacuum. The gel spots were completely covered with
trypsin for 10 min to saturate them with trypsin. After that, 60 µl of 50 mM ammonium bicarbonate
was added and the tubes were placed in an air circulation thermostat and incubated overnight at
37°C. Then the samples were transferred to a new microcentrifuge tube and added 60 µl of 2.5%
TFA to extra spots for 10 min. The volume of the combination was reduced to 20 µl and submitted
to mass spectroscopy analysis (MS/MS).
Nano RP HPLC-MS experiments were performed on an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 highperformance liquid chromatography system (Thermo Fisher) as described previously. EASYSpray PepMap C18 Column (75 μm × 15 cm, 3 μm, ThermoFisher, US) was used for separation.
The separation was achieved with a linear gradient from 3 to 40 % mobile phase B for 80 min at
a flow rate of 300 nL/min (mobile phase A: 1.95 % ACN, 97.95 % H2O, 0.1 % formic acid
(FA); mobile phase B: 79.95 % ACN, 19.95 % H2O, 0.1 % FA). LTQ-Orbitrap Elite mass spectrometer was operated in the data-dependent mode. A full-scan survey MS experiment
(m/z range from 400 to 1600; automatic gain control target, 1,000,000 ions; resolution at
400 m/z, 60,000; maximum ion accumulation time, 50 ms) was acquired by the Orbitrap mass
spectrometer, and ten of the intense ions were fragmented by collision-induced dissociation
(CID). The other conditions used included: capillary temperature of 200°C and collision energy
of 35 eV.
A Uniprot’s garlic database fasta file (3155 items, May 2017) was used for MS/MS spectra
matching as reported.[206] Raw data were analyzed by using Proteome Discoverer 1.4 (ThermoFisher) to search against Uniprot’s garlic database (3155 items, May 2017). Searching
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parameters were used as followed: fixed modification, carbamidomethyl (Cys); variable modifications, deamination (Asn), and oxidation (Met). Trypsin was selected as the enzyme, and two
missed cleavages were allowed. The mass tolerance for the precursor ions and the fragment ions
was set to 20 ppm and 0.5 Da, respectively. A false discovery rate (FDR) of 1 % was applied to
all data sets at the peptide level.
3.2.7

Western Blot

The cells (treated or not) were lysed with RIPA Buffer (150 mM NaCl, 1.0% Triton X100, 0.5% Sodium deoxycholate, 0.1% SDS, 50mM Tris pH 8.0, Roche phoSTOP and EDTA-free
protease tablets). The concentration of protein was analyzed using a DC assay. The samples were
loaded into the 4-20% SDS-PAGE and transferred the samples to a nitrocellulose membrane. After
1 h blocking, the membrane was incubated with primary antibody at room temperature for 2 hours.
The membrane was rinsed 3 times with TBST buffer. The membrane was incubated with a secondary antibody for 1 h at room temperature. Primary antibodies CD98, β-actin, and GAPDH were
diluted in 1:1000. The secondary antibodies goat anti-Rabbit IgG (H+L) ads-HRP, and goat antiMouse IgG (H+L) HRP Conjugate were diluted at 1:5000. The films were developed using a SERIES 2000A Processor film developer.
3.2.8

MTT Assay

To assess the potential toxicity of GDVs and digested GDVs, MTT assays were performed.
HepG2 cells were seeded in 96-well plates at a density of 5×105 cells per well and exposed to 100
µg/mL of GDVs for 24 hours. The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) is added to wells for 4 hours of incubation and reduced by metabolically active cells to
form the purple formazan dye crystals. The detergent solution was then added to the wells, solubilizing the crystals so that absorbance can be read using a spectrophotometer. The wavelength for
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measuring the absorbance of the formazan product was 570 nm. Untreated cells (controls) were
set to 100% viability.
3.2.9

Cell Uptake Assay

GDVs (100 µg) were incubated with 1 µM coumarin-6 at room temperature for 30 min and
the pellets were collected by ultracentrifugation after 3 rinses. The labeled GDVs were resuspended in cold PBS buffer and incubated with HepG2 cells at 37°C or 4°C.
Uptake studies were conducted by treating HepG2 cells at a concentration of 100 µg/mL
labeled GDVs for 1 to 6 h. The blocking test was carried by pre-incubating HepG2 with 10 µg/mL
of CD98 antibody for 1h before incubation with GDVs for 2 hours.[118, 184] GDVs were incubated with carbohydrates for 30 min before uptake assay.[22] The carbohydrates were D-glucose,
D-mannose, D-galactose, D-fructose, N-acetylglucosamine, lactose, and maltose. The results of
uptake were visualized and analyzed by immunofluorescence microscopy and flow cytometry described below.
3.2.10 Immunofluorescence Microscopy
For CD98 staining, the cells were fixed with 4% paraformaldehyde for 15 min at room temperature. The chamber slides were then rinsed 3 times using the DPBS. The cells were incubated
with 5% BSA for 1 h at room temperature (Blocking solution). Then, the cells were incubated with
CD98 (1:1000 containing 1% BSA and 0.01% of tween-20) antibody overnight at 4°C. The cells
were washed 3 times and incubated with the anti-rabbit IgG (1:4000) for 1 h at room temperature.
After 3 washes with the DPBS, the cells were stained with DAPI for 5 min. Finally, the cells were
washed with DPBS for 3 times and sealed with prolong gold antifade reagent.
After the uptake incubation, the medium was removed and the cells were washed with DPBS
3 times. The cells were fixed with 4% paraformaldehyde for 15 min at room temperature. Then,
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the slides were rinsed 3 times and incubated with the Alexa Fluor 568 phalloidin (1:1000) for 1 h
at room temperature, and the cells were stained with DAPI for 5 min. Finally, the cells were washed
with DPBS 3 times and sealed with prolong gold antifade reagent for fluorescent microscopy.
3.2.11 Flow Cytometry
After incubation with GDVs, the growth medium was removed and cells were rinsed 3
times DPBS. Cells were fixed with 4% paraformaldehyde acid (PFA) for 10 min at room temperature. After, the cells were resuspended in PBS with 5% FBS. Flow cytometric analysis was performed on a BD LSRFortessa flow cytometer (BD Biosciences), and data were analyzed using
FlowJo version 10. The gate was set using cells without any treatment (negative control) versus
Labeled GDVs-treated (positive control) cells measured by the FITC channel. The intensity of
uptake was calculated using the geometric mean of the population (n=10).
3.2.12 RT-qPCR
Total RNA was extracted from HepG2 cells using SpinSmart RNA mini purification kit
under the manufacture’s manual. The RNA was quantified by Synergy H1 plate reader (BioTek,
Winooski, USA). cDNA was synthesized from the total RNA using cDNA synthesis master mix
according to the manufacturer’s instructions. Gene-specific cDNAs were quantified by RT-qPCR
using SB-Green qPCR Master Kit. The GAPDH gene was used as a housekeeping gene in RTqPCR. Fold-induction was calculated using the Ct method: ΔΔCt= (CtTarget gene- CtHousekeeping gene) treatment-(CtTarget gene- CtHousekeeping gene) nontreatment, and result was calculated using the formulation 2-ΔΔCt.
Primers used for qRT-PCR: IL-6 Fwd: 5’-CAATCTGGATTCAATGAGGAGAC-3’, IL-6
Rvs:

5’-CTCTGGCTTGTTCCTCACTACTC-3’,

IFN-γ

Fwd:

5’-GCTT-

GAATCTAAATTATCAGTC-3’, IFN-γ Rvs: 5’-GAAGATTCAAATTGCATCTTTAT-3’.
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3.2.13 Statistical Analysis
Data are presented as mean and standard deviation (SD). A two-way ANOVA Analysis
was performed to obtain statistical differences among groups. The t-test was used for comparison
between the two groups and a P-value less than 0.05 was considered significant.
Results
3.3.1

The Physicochemical Properties of the GDVs

The size and shape of GDVs (Figure 3.1 A) and T4 GDVs (4h incubation with trypsin)
(Figure 3.1 B) were identified by TEM. Both sizes were less than 150 nm with a spheroid shape.
The T4 GDVs showed a multi-vehicle body structure. This might be caused by digestion which
destroyed surface proteins and rearranges the lipid structure.[204, 207] AFM study has shown the
morphology of digested GDVs and GDVs had no significant difference. The shapes of GDVs
(Figure 3.1 C) and T4 GDVs (Figure 3.1 D) were similar but not uniform, which may be a result
of the different membrane protein compositions due to enzymatic digestion. As shown in Figure
3.1 E and 3.1 F, the blue curve shows the size distribution by number and the red curve shows size
distribution by intensity. The size of GDVs by intensity ranged from 70-200 nm and the average
size was 191.8 ± 2.0 nm (Figure 3.1 E) and the size of T4 GDVs was ranged from 70-200 nm and
the average size is 178.6 ± 1.8 nm (Figure 3.1 F). The size distributions of GDVs and T4 GDVs
by number showed that GDVs or T4 GDVs have a diameter of around 100 nm.
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Figure 3.1: The physicochemical properties of garlic-derived nanovesicles (GDVs).
(A) The intact GDVs and (B) GDVs, which the surface proteins have been trypsin-digested for 4h
(T4 GDVs) were visualized by transmission electron microscopy (TEM). Atomic force microscopy images of (C) GDVs and (D) T4 GDVs were captured. The average size was measured by
the dynamic light scattering (DLS) method as well as the zeta potential respectively (E) The size
distribution of GDVs was measured by intensity (red) and number (blue), (F) The size distribution
of T4 GDVs was measured by intensity (red) and number (blue), as well as the (G) Zeta potential
distribution of GDVs and, (H) Zeta potential distribution of T4 GDVs.
The curves show a narrow size distribution listed in Table 2.1. The analysis of the size
curves after trypsin digestion showed that T4 GDVs slightly decreased. The DLS showed the sizes
were homogenous. The zeta potential analysis showed that the zeta potential of digested or
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undigested GDVs was negative, and around -31 mV (Figure 3.1 G and 3.1 H). It has been reported
that particles derived from edible plants (such as carrot, grape, grapefruit, and ginger) were quite
stable in simulated gastrointestinal solutions.[7, 204] Moreover, plant-derived nanovesicles
showed intact biology effects after oral administration indicating their stability in vivo. This latter
observation is interesting as such particles (size of 200 nm such as GDVs) are suitable for both
active and passive internalizations.[208, 209] Altogether, these observations established that the
differences in GDVs uptake by cells were only due to the deletion of surface membrane proteins
on GDVs.
Table 3.1: Summary of GDVs’ and Trypsin-digested GDVs’ size and zeta potentials.
Sample

size (d. nm)

PDI

Zeta (mV)

GDVs

191.8±2.0

0.217±0.011

-32.3±0.86

T1 GDVs

178.6±1.8

0.171±0.017

-31.5±1.2

T2 GDVs

175.7±4.2

0.199±0.008

-34.9±0.60

T3 GDVs

170.8±1.6

0.170±0.015

-33.2±0.70

T4 GDVs
175.2±1.7
0.188±0.018
-30.8±1.0
Table 2.1: Summary of the size and zeta potentials of the intact GDVs and GDVs which the surface proteins have been trypsin-digested for 4h.

3.3.2

Uptake kinetics of GDVs is correlated to the surface expression of CD98 on
HepG2 cells

The global incidence of nonalcoholic fatty liver disease (NAFLD) is 25%, which induced
a strong burden on society.[44] In the United States, this increased incidence of NAFLD was associated with increased liver disease mortality.[210] The goal of this paper is to develop a preliminary understanding of the uptake mechanisms of the GDVs and their potential therapeutic effects
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to apply them further as a nanotherapeutic for inflammatory and liver disease. Thus, HepG2 cell
was used in this study. As shown in Figure 3.2 A, we studied the cytotoxicity of GDVs on HepG2
cells and found that both the undigested and digested GDVs were not cytotoxic in HepG2 cells
after 24-hour incubation with 100 µg/mL of GDVs (more than 98% of viable cells). Hence, GDVs
uptake within 24 hours of exposure was used to track GDVs endocytosis.
The uptake of GDVs by HepG2 cells was concentration- and time-dependent. As shown in
Figure 3.2 B, the uptake of GDVs by HepG2 cells was investigated by flow cytometry. GDVs
were tagged with coumarin-6. The kinetics uptake was studied at the range of concentration of
coumarin-6 tagged GDVs of 25 to 150 µg/mL for 6 h. GDVs were incubated with HepG2 cells for
different periods (1h to 6h at 100 µg/mL of GDVs). The uptake was measured by flow cytometry
(Figure 3.2 C), and it showed the GDVs uptake was fast and reached a plateau after 1 hour of
incubation.
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Figure 3.2: Uptake of GDVs is dependent on the GDVs surface protein integrity and
CD98 expression level in HepG2 cells.
(A) MTT cell viability assay on HepG2 cells after incubation with GDVs for 24h (the concentration of GDVs was 100 μg/mL, the values represent means ± SD. Data represents of n=6 determinations). The uptake of GDVs was (B) concentration-dependent and (C) time-dependent for the
first hour and reached a plateau after 2h. (B) GDVs were incubated with HepG2 cells for 6 hours
and (C) HepG2 cells were incubated with GDVs at a concentration of 100 μg/mL. The values
represent means ± SD. Data represents n=3 determinations). (D-F) illustrates the uptake of GDVs
as a function of the CD98 level of expression. (D) The lowest level of CD98, as the downregulation, was conducted by CD98 siRNA using oligofecatmine, (E) basal level of CD98 expression on
HepG2 cell, and (F) the highest level of expression of CD98 in HepG2 cells (stimulation by 10
μg/mL of LPS for 24 h).
The study also investigated the kinetics uptake of GDVs on cells (HepG2) expressing differential levels of CD98 expression. Many groups have found that LPS stimulation increased the
expression level of CD98 mRNA.[132, 171, 211] In this study, the three differential expression
levels of CD98 proteins were accessed by LPS-stimulation (upregulation), regular condition, and
CD98 siRNA (downregulation). Both immunofluorescent images and Western blot successfully
confirmed that CD98 express at different levels on the HepG2 cell surface. The basal level (HepG2
cells under regular culture condition) was set as the control (Figure 3.3 B). A higher CD98 expression level was observed by supplementing the cell medium with LPS (Figure 3.3 A), while a lower
level was found by transfecting cells with CD98 siRNA (Figure 3.3 C). The western blot (Figure
3.3 D, Appendix Figure 5-0.4 A) verified that the experiment was able to generate differential
CD98 expression with HepG2 cells (control, LPS, siRNA). Since the CD98 is already highly

66
overexpressed in liver cancer cells, changes in the amount of CD98 were further investigated by
the quantification of the western blot films. The quantification of western blots (Appendix Figure
5-0.4 B) showed that LPS can increase the expression of CD98 by 10% when compared with the
control group (HepG2 cell under regular culture condition). In contrast, CD98 siRNA significantly
decreased CD98 expression by 37%.
By comparing Figure 3.3 A-C, the effect of CD98 cell expressions on the uptake of GDVs
was able to be observed. The intensity of uptake was detected by using CD98 silenced HepG2
cells (Figure 3.2 D), untreated HepG2 (Figure 3.2 E) cells and LPS stimulated HepG2 cells (Figure
3.2 F). As shown in Figure 3.2 D-F, the GDVs uptake was proportionally increased with the expression of CD98 as shown by the position of the peak maximum and the area under the curve of
each flow cytometry experiment. Comparing each line within the same plot, it was displayed that
for any CD98 expression, the surface protein digestion reduced the uptakes of GDVs. Similarly,
in literature, proteins on membranes of exosomes were digested by protease K which inhibited the
uptake by cells.[22] Trypsin-digested GDV uptake was significantly decreased compared to native
GDVs demonstrating the importance of ligands present on the surface. Also, comparing each curve
of the same color in the 3 different experiments, it was shown that for the same GDVs surface
proteins profile, the uptake of GDVs was correlated to CD98 expression. This result was further
demonstrated by investigating the uptake of GDVs with differential CD98 expression by fluorescent microscopy (Figure 3.4).
The intensity of uptake was also quantified by the geometric mean and as shown in Figure
3.3 E. T4 GDVs were uptaken less than intact GDVs by HepG2 cells. For the uptake of GDVs, it
was shown that silencing CD98 significantly decreased the uptake of GDVs by 33.85% compared
with that in HepG2 cells under regular culture conditions. In contrast, LPS-stimulated HepG2
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increased the uptake of GDVs by 17.16%. These results together showed the uptake of GDVs by
HepG2 cells was correlated to the level expression of CD98 on HepG2 cells.
The uptake of GDVs was visualized by fluorescence microscopy (Figure 3.4). Figure 3.4
showed the uptake of GDVs (i) by LPS-stimulated HepG2 cells (first panel), (ii) by regular HepG2
cells (second panel), and (iii) by HepG2 cells treated with CD98 siRNA (third panel). As expected,
there is no coumarin-6 signal (GDVs) in the cells without GDVs (PBS column in Figure 3.4). The
fluorescent study showed clearly that the intact GDVs group was significantly uptaken more than
trypsin-digested GDVs groups. Within the GDVs supplemented cells column, it was also observed
that the kinetics of GDV uptake by HepG2 cells directly correlated with the CD98 expression
levels. CD98 downregulation (line 3 in Figure 3.4) showed a significant decrease in the endocytosis of GDVs. These indicated that CD98 expression in the HepG2 cell plays an important role in
the recognition and uptake process of GDVs.
3.3.3

Important Presence of II Lectin on GDVs Surface

After establishing that CD98 expression in HepG2 cells is a key factor for GDVs uptake,
a proteomics study was carried out to investigate which proteins on the GDVs’ surface might interact with CD98.
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Figure 3.3: CD98 expression level is significantly involved in GDVs uptake.
Differential levels of expression of surface CD98 (red) were stained by stimulating HepG2 cells
with 10 μg/mL of LPS for 24 h (A, the highest expression of CD98), by regular cell culture of
HepG2 (B, basal CD98 expression), and by treating HepG2 cells with CD98 siRNA using oligofectamine (C, lowest expression of CD98). The CD98 was stained in red and the nuclear was
stained in blue (DAPI). (D) Western blot showed a level of CD98 after different treatments (LPS,
control, and siRNA). (E) CD98 expression is directly correlated with GDVs uptake. Uptake was
monitored by flow cytometer and the result was calculated relatively to the uptake without treatment, considered as 1.0.
GDVs’ Surface proteins were isolated using a standard protocol of membrane isolation for
cells. GDVs’ surface proteins were digested using trypsin (0.25%) and separated using SDS-Page
(4-15%, 135 V, 80 min). As shown in Figure 3.5 A, the channels from left to right are respectively
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protein markers, undigested plasma proteins from GDVs (undigested), and GDVs’ plasma proteins
digested by trypsin for 4h (digested). While fewer bands in the GDVs’ plasma membranes digested
by the trypsin channel indicate that most proteins were degraded, the “undigested” plasma membrane proteins show interesting significant bands (corresponding to dominant presence surface
proteins). As shown in Figure 3.5 A, the bands between 110 kDa, 55kDA, 25-37 kDa, 20-25 kDa,
and 15kDa were observed. These bands were cut off the gel and analyzed by mass spectroscopy
(MS/MS) as described in the supplemental method section. The result of protein identification is
shown in Figure 3.5 B (table section). Some proteins (abundant in garlic) were found from protein
identification, such as alliinase, ribulose bisphosphate carboxylase large chain, and ATP synthase
subunit beta. Interestingly, a mannose high-affinity lectin, i.e., II Lectin was found. Because II
Lectin had been investigated prior for specific interaction with certain surface cell receptors,[65,
212] it was decided to further study the specific interaction.
3.3.4

Specific Interaction Between GDVs Surface Ligands (II Lectin) and CD98

The mechanism of extracellular vesicle endocytosis is diverse, including membrane fusions, protein interactions, and lipid raft-mediated internalization.[19] As shown in Figure 3.6 A,
a significant “left”-shift of the fluorescent channel peak was observed when the GDVs were exposed to cells (2 h) at 4°C versus 37°C. This observation supports the fact that the uptake of GDVs
by mammalian cells was significantly inhibited under 4°C, indicating that a predominant part of
the uptake of GDVs by cells was energy-dependent. In Figure 3.6 B, the co-localization study of
CD98 (stained in red) and undigested GDVs (stained in green) showed significant co-localization
clusters visualized in yellow. To confirm that plasma membrane proteins were playing a key role
in endocytosis, the same experiments (6-hour incubation, 37°C) were conducted after respectively
1h- (Figure 3.6 C) and 4h- (Figure 3.6 D) digestion of GDVs’ plasma membranes proteins by
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trypsin. The results of this fluorescent microscopy study showed that T1 GDVs (1h trypsin-digestion, Figure 3.6 C) and T4 GDVs (4h trypsin-digestion, Figure 3.6 D) had significantly fewer colocalization signals than the undigested GDVs (Figure 3.6 D). Combining the scientific literature
with the results of the flow cytometry, mass spectroscopy, and fluorescent microscopy experiments, it was concluded that lectin family proteins present on GDVs playing a major role in the
endocytosis of GDVs mediated by CD98 interactions. As a reminder, lectins are a type of protein
that can bind to glycoproteins including CD98 glycoprotein, and lectins are found in mammalian,
bacteria, and plants. Animal lectin such as galectin-3 was proven to be a ligand of CD98 and plant
lectin such as GSL-IB4 has been reported to have similar carbohydrate-binding specificities with
galectin-3.[81, 82, 213]

Figure 3.4: Cross study of the modulation of GDVs endocytosis by HepG2 cells by
tuning the expression level of CD98 on HepG2 cells and the integrity of surface proteins of GDVs.
HepG2 cells were incubated with 100 µg/mL GDVs for 6 h excepted column A (noted PBS) which
represents HepG2 cells without GDVs. The GDVs were labeled with coumarin-6 (green), HepG2
cells were stained for actin with Phalloidin (red) and nuclei were stained with DAPI (blue).
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Vertically, other columns (B, C, D, E, and F) represent a different “type” of GDVs treatment. B,
C, D, E, and F columns represent respectively intact GDVs (GDVs in B), 1h-trypsin-digested
GDVs (T1 GDVs in C), 2h-trypsin-digested GDVs (T2 GDVs in D), 3h-trypsin-digested GDVs
(T3 GDVs in E), and 4h-trypsin-digested (T4 GDVs in F). Horizontally, line 1 (noted LPS) represents LPS-stimulated HepG2 cells (overexpressing surface CD98 on HepG2 cells). The second
line (noted HepG2) represents the basal expression of CD98 on HepG2 cells. Finally, line 3 (noted
CD98 siRNA) shows HepG2 cells with lower expression of CD98 (blocked by pre-treatment with
CD98 siRNA).
Based on the literature and the corroborating results, it is concluded that the interaction
between a ligand (II Lectin) on GDVs and CD98 glycoprotein determines the uptake of GDVs in
HepG2 cells.[19] The next step aims to demonstrate that CD98 is the receptor involved on the side
of the HepG2 and that the specific ligand on GDVs is II Lectin significantly found on the surface
of GDVs by MS/MS.
3.3.5

CD98 is the Main Receptor of GDVs via II Lectin Coated GDVs

As shown previously in this study (Figure 3.3 E), the downregulation of CD98 by its specific siRNA significantly inhibit the uptake of GDVs by 33% and decreased the co-localization
of CD98 and GDVs demonstrating that the uptake was highly related with CD98 on the side of
the HepG2 membrane. To further confirm this, HepG2 cells were pre-incubated with CD98 antibodies before conducting the flow cytometry uptake assay. As observed in Figure 3.6 E, a significant “left-shift” of the fluorescent signal related to endocytosis of GDVs by HepG2 cells was
noticed. Based on Figure 3.6 E, the uptake of GDVs after blocking CD98 receptors on HepG2
cells with a specific CD98 antibody (10 μg/mL, 1h), decreased as much as 47.01%. These results
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combined with the previously described data in this study definitively set CD98 as the main receptors on HepG2 cells involved in endocytosis.
Thus, the goal was to demonstrate that “on the other side’, II Lectin protein was the ligand of CD98. To confirm this hypothesis based on MS/MS results and scientific literature, we
deduced that if the hypothesis was right, the uptake of GDVs could be inhibited by pre-incubated
GDVs with free mannose highly bounding lectin.[22] The strategy was to block lectin via free
mannose and observe the potential effects on the endocytosis of GDVs by HepG2 cells. To complete the study, it was decided to experiment on the different types of carbohydrates (mono- or
disaccharides). The choice of free carbohydrates was defined by literature search where it is
clearly shown that lectins are a family of proteins with a high affinity to mannose and other carbohydrates (i.e., glucose,[214] mannose,[215] galactose,[216] fructose,[217] N-Acetylgalactosamine (noted GalNac),[218] lactose,[219] and maltose. [220]). It was demonstrated that the II
Lectin has a high affinity for mannose compared with other sugars.[91, 221] The uptake of
GDVs after pre-incubation with free carbohydrates (150mM) was investigated using flow cytometry (Figure 3.6 F). The GDVs without incubation with carbohydrates (noted control in Figure
2.6F) was normalized as 100%. As shown in Figure 3.6 F, the highest relative decrease (-44%
compared to control) of the uptake of GDVs by HepG2 cells was caused by pre-incubation of
GDVs with the mannose. Notably, galactose pre-incubation decreased uptake by 30%, while glucose did not affect the uptake efficiency. Lactose-, GalNac-, Maltose-, and Fructose- pre-incubations did not significantly modify the uptake of GDVs by HepG2 (less than 5% change). The
structures of those different carbohydrates are shown in Figure 3.7. The data indicates that the
uptake of GDVs was highly inhibited by mannose pre-incubation strongly supporting the role of
the lectins on GDVs surfaces. Taken together, it can be concluded that CD98 is a key receptor
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for GDVs uptake and that mannose pre-incubation coupled with MS/MS results strongly supports that the interaction with CD98 is lectins-dependent on GDVs surface side.

Figure 3.5: II Lectin presence on the surface of intact GDVs.
(A) Gel analyses have shown that the surface proteins of GDVs were digested and the gel was
stained with Coomassie blue. The three lanes of protein samples from left to right are a marker,
intact GDVs, and T4 GDVs (4h-trypsin-digested GDVs) respectively. (B) represent proteins
found in protein identification.
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Figure 3.6: CD98 is the main receptor of GDVs via II Lectin-coated GDVs.
(A) Uptake of GDVs by HepG2 cells were temperature-sensitive as shown by the endocytosis
studied through flow cytometry at 4°C versus 37°C. The “left-shift” signal of fluorescence at 4°C
showed a decrease of intact GDVs uptake by HepG2 cells compared to 37°C. (B) Co-localization
of intact GDVs (green) with CD98 expressed on HepG2 cells (red), (C) co-localization of 1htrypsin-digested GDVs (T1 GDVs in green) with CD98 expressed on HepG2 cells (red), (D) colocalization of 4h-trypsin-digested GDVs (T4 GDVs in green) with CD98 expressed on HepG2
cells (red). HepG2 cells were incubated with 100 µg/mL GDVs for 6 h. The GDVs were labeled
with coumarin-6 (green), CD98 was stained in red and cell nuclei were stained with DAPI (blue).
The co-localization GDVs-CD98 appears in yellow. (E) Uptake of GDVs by HepG2 cells were
CD98-sensitive as shown by the endocytosis studied by flow cytometry with a pre-incubation of
cells with CD98 antibody (CD98 Ab) versus no blocking. The “left-shift” signal of fluorescence
with the CD98 Ab showed a decrease of intact GDVs uptake by HepG2 cells compared to cells
without Ab. (F) Flow cytometry quantification of the GDVs uptake by HepG2 cells after pre-
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incubation of GDVs with 150 mM of different saccharides were glucose, mannose, galactose,
fructose, N-Acetylgalactosamine (noted GalNac), lactose, and maltose. Relative Uptake was calculated and standardized to the uptake of GDVs by HepG2 cells without treatment considered as
100%. Results are displayed in relative percentages ± S.D. The results shown are representative
of three independent experiments performed in duplicate.

Figure 3.7: The structure of carbohydrates used in the GDVs pre-incubation.
(A) D-glucose, (B) D-mannose, (C) D-galactose, (D) D-fructose, (E) N-acetylglucosamine, (F)
Lactose, (G) Maltose.
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3.3.6

GDVs Uptake by HepG2 Cells Reduced the LPS-induced Inflammatory

Knowing the biological effect of GDVs on liver cells could help understand the benefit of
garlic in the human diet. The IFN-γ and IL-6 have been reported to play an important role in many
pathological conditions, such as inflammatory, carcinogenic, and infectious.[171, 222-224] The in
vivo amount of LPS was majorly produced by the gut gram-negative bacteria and the LPS was
considered as the inducer of hepatic inflammation and colitis (gut-liver axis).[225-227] LPS
mainly stimulated the liver cell by interacting with the different toll-like receptors. The induction
of IL-6 by LPS is through the MyD88-dependent signaling pathway, while the generation of IFNγ was in a MyD88-independent way.[228] As shown in Figure 3.8, the anti-inflammatory effects
of GDVs or T4 GDVs were tested on HepG2 cells with different expression levels of CD98. The
regular HepG2 cells control group was treated with PBS only and their relative expressions of
IFN-γ (Figure 3.8 A) and IL-6 (Figure 3.8 B) mRNA were used as the baseline and set to 1. After
the treatment of GDVs or T4 GDVs, the expression levels of IFN-γ were reduced by 42% (p<
0.001) and 29% (p< 0.05), respectively. A similar result was observed in the IL-6 mRNA expression. Moreover, more inhibition on the expression of IFN-γ and IL-6 was found in GDVs treated
groups. The LPS stimulation increased the expression level of IFN-γ and IL-6.[229] The expression of IFN-γ and IL-6 mRNA on LPS-treated HepG2 cells was significantly inhibited by applying
GDVs or T4 GDVs. Interestingly, the expression level of IFN-γ mRNA in GDVs treated LPSstimulated HepG2 cells was significantly lower than that induced by its counterpart (T4 GDVs).
The stronger anti-inflammatory effects were observed on GDVs treated groups rather than the T4
GDVs treated groups, confirming the higher internalization was of GDVs rather than T4 GDVs by
HepG2 cells. After the treatment of GDVs, the level of IFN-γ and IL-6 mRNA was close to the
baseline, indicating the strong anti-inflammatory effect of GDVs. Silencing CD98 decreased the
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expression of IFN-γ and IL-6. Thus, even treated with GDVs or T4 GDVs, there was no significant
difference in the expression level of IFN-γ and IL-6. Recently, it was reported that CD98 could be
an inducer receptor in non-alcoholic fatty (NAFLD) liver disease, and CD98 siRNA-loaded nanoparticles were shown therapeutic potential for this disease. These nanoparticles downregulated the
expression CD98 both in vitro and in vivo, decreasing the level of NAFLD-related pro-inflammatory cytokines such as TNF-alpha, IFN-gamma, and IL-1beta.[171] These results associated with
previous conclusions suggested that GDVs showed broad anti-inflammatory potentials against the
LPS-induced inflammatory on liver cells. Taken together, GDVs could be a promising strategy to
reduce the anti-inflammatory process in pathologies like fibrosis or colitis.

Figure 3.8: Intact GDVs had a biological effect on reducing the expression of an
anti-inflammatory gene (Interferon γ noted IFN-γ and Interleukin 6 noted IL-6).
HepG2 cells were incubated without GDVs or digested GDVs (control noted control), with GDVs
(100 µg/mL), or with T4 GDVs (100 µg/mL) for 24 hours, and total RNAs were isolated by using
the RNA extraction Kits. The CD98 expression was regulated by LPS, CD98 siRNA, and without
any treatment (Regular). HepG2 cells without any treatments were set as 1. Values represent means
± S.D. Data are represents n = 3 determinations, * p<0.05, ***p<0.001. Normalization of results
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has been done over a gene known as stable expression (housekeeping gene) of gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH).
Discussion
This study contributes to understanding the communications between GDVs and mammalian cells. Edible plants have been consumed by humans for thousands of years, which shows the
great biosafety of garlic and how the provided dietary antioxidants show benefits to many types of
chronic disease including NAFLD.[230, 231] Garlic has been shown to provide broad anti-inflammatory effects via many different bioactivated compounds. However, no histologically clear results were found in the garlic NAFLD trials.[232] This might be caused by the difficulty for bioactivated compounds to access the cytosol.[233] Many types of cargoes have been found in mammalian cell-derived vesicles. As reported, the exosomes contained more than 1000 types of proteins and RNA.[234, 235] The PDNs carry small molecular, RNA, and proteins, similar to their
animal cell counterparts. Unlike the free compounds, PDNs not only protect the compounds but
also enhance the bioactive compounds' penetration into deep tissues.[11] Thus, PDNs can amplify
the benefits of the edible plant by enhancing the bioactive compounds delivery efficiency.
The GDVs were characterized by DLS, TEM, and AFM, which are the most common technologies for characterizing nanoparticles. The DLS showed that the size and zeta potential of
GDVs are not significantly changed after trypsin digestion. The AFM study has shown that the
morphology of digested GDVs and GDVs has no significant difference. Thus, it can be concluded
that the digested proteins were surface proteins of GDVs. Together with the nontoxic properties
of GDVs, it can be concluded that GDVs can be the promising oral administrative formulation for
drug delivery as other PDNs.[8, 11]
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In the literature, a variety of fluorophores (PHK-26, PHK-67, CFSE, Dil, coumarin-6, and
DiD) have been used to label the lipid-based vesicles for the microscope visualization and flow
cytometry analysis.[9, 236-239] Excess unincorporated dyes were removed by ultracentrifugation
or column before carrying the uptake studies, which proved the fluorescent signals detected in
cells were caused by the internalization of labeled vesicles. Our results showed the CD98 expression level was highly associated with the labeled GDVs internalization amount. Previous studies
showed that CD98 played an important role in regulating drugs to pass the blood-brain barriers
(BBB) and drug delivery.[115, 240]
The CD98 receptor is connected to II Lectin by exploring surface proteins via MS/MS and
blocking II Lectin via mannose pre-incubation with GDVs. As reported, the interactions between
lectin and sugar are involved in the uptake of exosomes. The interactions can be affected by appearing corresponding sugars or lectins. For example, the mechanism for dendritic cells uptake
dendritic cells-derived exosomes is via the C-type lectin/mannose (glucosamine)-rich CLR interaction. Thus, this internalization can be inhibited by presenting mannose.[241] In another research
study, researchers found that galectin-5 was present in the surface of rat reticulocyte cell exosomes
and the internalization by macrophages was inhibited after adding galectin-5.[239] Plant lectins
could have a biological function on mammalian cells such as inducing apoptosis and autophagy
[242]. GSL-IB4, a plant lectin, could bind to CD98, stimulating Ca2+ channels on Jurkat cell membranes [82]. It has been reported that garlic lectins showed a high affinity to mannose and as stated
before, some parts of glycans on CD98 consist of mannose oligosaccharides [221]. The co-localization and II Lectin blocking by mannose studies showed that the lectins on GDVs interact with
HepG2 cells via CD98 glycoprotein.
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As said, many factors parallelly lead to inflammation in the NASH, leading to difficulty in
the development of an effective drug. The potential anti-inflammatory benefits of GDVs were
demonstrated by using HepG2 cells. Hepatic IL-6 level in NASH patients is significantly higher
when compared with that in healthy volunteers or NAFLD patients.[243] The IFN-γ-deficient mice
were more resistant to a methionine- and choline-deficient high-fat-induced hepatic inflammatory.
And IFN-γ might promote the development of NASH by stimulating the macrophages secreting
TNF-α.[244] GDVs carrying a mixture of natural bioactive compounds, making them able to mediate the anti-inflammation effect via different pathways.
Conclusion
In summary, this study demonstrated that the CD98 glycoprotein (rich in mannose motifs) on HepG2 cells is involved in the internalization of GDVs via binding with lectin-type proteins. As CD98 is highly expressed in many types of cancers, intestinal inflammation, and nonalcoholic fatty liver disease, the potential therapeutic interests of oral administration of native
GDVs in different disease models can be investigated. GDVs are great therapeutic potentials to
target CD98 based on their significant anti-inflammatory effect and high non-toxicity. GDVs
may open a novel therapeutic platform for acute or chronic diseases via oral administrations.
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Scheme 1: Internalization of Garlic-derived Exosome-like Nanovesicles (GDEs) by HepG2
is triggered by interaction with CD98
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4

CONTRIBUTIONS AND FUTURE DIRECTIONS

Plant-derived nanovectors and their effects on anti-inflammation and steatosis
Upon joining the laboratory, great efforts were being made on the testing of plant nanovectors and their effects on inflammation and steatosis in NAFLD. The training was obtained in
all forms of nanovector isolation to the biological testing (Western blot, PCR, ect). Major contributions to the project were carried out during the late stages of the project where the in vivo experiments were progressed. Assistance was given to performing the daily gavage of the garlicderived nanovectors to the mice in addition to the daily weight monitoring. These experiments
were carried out as a 9-week concurrent treatment with the high-fat diet and as an 8-week on the
high-fat diet followed by 2 weeks of daily gavages of the garlic-derived nanovectors. The goal of
the study was to determine the overall effect of the garlic-derived nanovectors as a preventative
and therapeutic method for managing the development and progression of NAFLD. At the end of
the experiments, the blood was collected via terminal blood collection and the liver, colon, kidney, and spleen were harvested for further analysis. The procedure and weights are depicted in
Figure 4.1. It was documented that the overall weight of the mice was not significantly different
between the PBS and the garlic gavage groups (Figure 4.1 B). This demonstrates that the garlicderived nanovectors did not affect overall visceral fat as was seen through daily monitoring. It is
also worth noting that the weight loss of the mice in the post-treatment was most likely due to the
shock of the mice being gavaged after the initial 8-week period on the high-fat diet. Weights
gradually increased at a similar rate after the initial gavage.
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Figure 4.1: Mice treated with garlic-derived nanovectors exhibited similar weight loss
trends to that of the control mice group.
A) Mice were fed with an HFD for 9-10 weeks with a daily gavage of 0.5 mg/mL garlic-derived
nanovectors and 1x PBS after week 8 and throughout HFD for 9 weeks. B) Weight gain trends
for mice recorded periodically through diet and treatment. (Figure used from Brandon Canup’s
dissertation with permission to allow for an overview [245])
The overall results will be highlighted in Brandon Canup’s dissertation and possible future publication.[245] The initial results that were obtained in the laboratory showed that the garlic-derived
nanovectors were very good at suppressing CD98 upregulation in HepG2 cells after LPS and palmitic acid stimulation. The results from these experiments were promising for the directions of
the in vivo experiments. The results of the in vivo experiments showed that CD98 was successfully downregulated in both the concurrent and post-treatment with the garlic-derived nanovectors (Figure 4.2). This response to the garlic-derived nanovectors was similar to the prior results
in the laboratory.
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Figure 4.2: Mice treated with garlic derived nanovectors exhibited downregulation of CD98
mRNA and protein expression
A) Mice were fed with an HFD for a period of 9 weeks with a daily gavage of 0.5 mg/mL
garlic-derived nanovectors and 1x PBS for 9 weeks. B) Mice were fed with an HFD for a period
of 10 weeks with a daily gavage of 0.5 mg/mL garlic-derived nanovectors and 1x PBS after
week 8 and throughout HFD for a total of 10 weeks. (Figure derived from data in Brandon
Canup’s dissertation with permission [245])
Since the downregulation of CD98 was observed in the liver tissue of the treated mice,
the overall effect on the liver was examined by histology. The results of the CD98 downregulation demonstrated downregulation in the lipid vacuoles in the liver tissue as analyzed by H&E
staining (Figure 4.3) which was similar to the results reported in the work produced using the
CD98 siRNA-loaded polymer nanoparticles.[171]
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Figure 4.3: Mice treated with garlic derived exosomes exhibited attenuation of lipid
vacuoles in the livers of high-fat-diet-fed mice
Hematoxylin and Eosin staining of liver tissue from in vivo experiments. A) Mice were
fed with an HFD for a period of 9 weeks with a daily gavage of 0.5 mg/mL garlic-derived nanovectors and 1x PBS for 9 weeks. B) Mice were fed with an HFD for a period of 10 weeks with a
daily gavage of 0.5 mg/mL garlic-derived nanovectors and 1x PBS after week 8 and throughout
HFD for a total of 10 weeks. (Figure derived from data in Brandon Canup’s dissertation with
permission [245])
The promising results obtained during the training period propagated the project outlined
in Chapter 3 and which was published in ACS Omega.[246] The goal was to question if CD98
played a role in the internalization of the garlic-derived nanovectors. Due to the initial increase in
CD98 expression in the in vitro and in vivo models that were tested, it was speculated that the increased expression of CD98 would also allow for increased garlic-derived nanovectors uptake.
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Thereby allowing the garlic-derived nanovectors to enact their therapeutic benefits. With this
prior knowledge in hand, the anti-inflammatory characteristics of the garlic-derived nanovectors
were also confirmed. Thus, the experiments described in Chapter 2 and the material presented in
Brandon Canup's dissertation allow for the understanding of the uptake mechanism and overall
benefit of utilizing garlic-derived nanovectors for the downregulation of CD98 in the liver.
Future directions
The endeavors undertaken to investigate the roles of CD98 in liver inflammation and its
association with plant nanovectors internalization in the laboratory are still incomplete. Herein,
the role of CD98 and its interaction with garlic-derived nanovectors was investigated. Other reports for CD98 and its relation to the plant-derived nanovectors have been documented, but not
published [1]. One of the issues that using plant-derived nanovectors as therapeutic tools is the
lack of information on characteristics such as lipid constitution, protein cargo, nucleic acid cargo,
and small molecule cargo. Screening multiple plant-derived nanovectors then becomes a costly
endeavor. In addition, the controversy over the identity of plant-derived nanovectors as associated with plant-derived exosomes. Currently, there are a lot of reports that have demonstrated
commonality between exosomes derived from mammalian species such as similar surface markers and cargos. This is not the case with the plant-derived nanovectors which as of writing this
dissertation, there are not similar surface markers that can be used to identify if the plant nanovector is an exosome. The biogenesis of the plant-derived exosome has yet to be fully unraveled
since the mechanism may or may not be similar to that of the mammalian counterpart. Great efforts must be made to analyze these fundamental problems to ensure quality control and reproducibility among research laboratories.
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The logical steps of the experiments thus far would be to analyze the other plant-derived
nanovectors studied in the laboratory. The lab has analyzed grapefruit and carrot-derived exosomes in the in vitro models. It would provide great insight to see if they would behave similarly
with CD98. For the progress of the internalization experiment, a knockout study of CD98 using
mice would elucidate if the results could be translated in vivo. The experiment could be determined using flow cytometry analysis after the successful development of the CD98 knockout
mice. The knockout mice could also be fed with a high-fat diet for a period of 9 weeks with a
daily 1X PBS and garlic-derived nanovectors to validate the previous publication and study performed in the lab. The next step would be optimizing the garlic-derived nanovectors to be a therapeutic vehicle to sites with known upregulation of CD98. There is a great variety of different
avenues in which the project could progress given time and funding.
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APPENDIX
Appendix Table 1. Human Primers (h = human and m = mice)
Gene Name
Forward

Reverse

hGAPDH

5’-TTGGTATCGTGGAAGGACTCA -3’

5’-TGTCATCATATTTGGCAGGTTT-3’

hIFN-γ

5’-GCTTGAATCTAAATTATCAGTC-3’

5’-GAAGATTCAAATTGCATCTTTAT-3’

mIFN-γ

5’-TCAAGTGGCATAGATGTGGAAGAA-3’

5’-TGGCTCTGCAGGATTTTCATG-3’

hIL-6

5’-CAATCTGGATTCAATGAGGAGAC-3’

5’-CTCTGGCTTGTTCCTCACTACTC-3’

hCD98

5’-GCTTGCAGCCAAAACTCCAG-3’

5’-CCAACTACCGGGGTGAGAAC-3’

mCD98

5’-GAGGACAGGCTTTTGATTGC-3’

5’-ATTCAGTCGCTCCCCAGTG-3’

hCox-2

5’-GGTCTGGTGCCTGGTCTGATGATC-3’

5’-GTCCTTTCAAGGAGAAATGGTGC-3’

mCox-2

5’-TACCAGTCTCTCAATGAGTACC-3’

5’-TGGTAGGCTGTGGATCTTGCACATTG-3’

hTNF-α

5'-ATCTACCTGGGAGGCGTCTT-3’

5'-GAGTGGCACAAGGAACTGGT-3'

mTNF-α

5’-AGGCTGCCCCGACTACGT-3’

5’-GACTTTCTCCTGGTATGAGATAGCAAA-3’

m36b4

5’-TCCAGGCTTTGGGCATCA-3’

5’-CTTTATCAGCTGCACATCACTCAGA3’
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Appendix Figure 5-0.1: The shape of CD98 siRNA-loaded NPs was visualized by
Atomic Force Microscopy (AFM).
Atomic force microscopy (AFM) image of CD98 siRNA-loaded NP. [171]
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Appendix Figure 5-0.2: FITC-labeled siRNA-loaded NPs were uptake by the HepG2
cells.
Fluorescent microscopy (grayscale picture) of HepG2 cells after overnight incubation with
FITC-labeled siRNA-loaded NPs (200µg/mL). The scale bar is 50 µm. [171]
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Appendix Figure 5-0.3: The liver, spleen, and kidney from HFD mice without any FITClabeled siRNA-loaded NPs treatments do not show the signal of FITC.
The actin in kidney, spleen, and liver tissues was stained with the phalloidin (Alexa Fluor 568)
and the nuclei were stained with DAPI. The scale bar is 50 µm.
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Appendix Figure 5-0.4: The CD98 expression level in HepG2 cells was decreased by using
CD98 siRNA and increased by LPS-stimulation.
(A) the expression level of CD98 under three different treatments (LPS, control, CD98 siRNA).
(B) the expression amount was quantified. T-test was used to analyze the significance.
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Appendix Figure 5-0.5: The secondary antibody (anti-Rabbit, tagged with Alexa Fluor 568)
does not show the obvious signals in staining the HepG2 cells.
Same staining procedures with the CD98 staining except that CD98 primary antibody is not applied. The secondary antibody (anti-Rabbit) is tagged with Alexa Fluor 568 (if it is present, it is
indicated as red) and the nuclear was stained in blue (DAPI). The scale bar is 50 µm.

